日本臨牀　別冊　血液症候群（第3版）III

出版社： 日本臨牀社
発行日： 2023-11-30
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 血液症候群（第3版）III―その他の血液疾患を含めて―
電子書籍版： 2023-11-30 （第3版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

19,800 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

目次

  • 特集　血液症候群（第3版）III
    　　　―その他の血液疾患を含めて―

    V．血小板の異常
    　1．血小板増加症
    　　(1)反応性血小板増加症
    　2．血小板減少症
    　　(1)特発性血小板減少性紫斑病
    　　(2)二次性血小板減少症
    　　(3)その他の血小板減少症
    　3．血小板機能異常症
    　　(1)先天性血小板機能異常症
    　　(2)後天性血小板機能異常症

    VI．血管障害による出血傾向
    　1．先天性血管性紫斑病
    　　(1)遺伝性毛細血管拡張症
    　　(2)Ehlers-Danlos症候群
    　2．後天性血管性紫斑病
    　　(1)DNA自己感作性紫斑病
    　　(2)自己赤血球感作性紫斑病
    　　(3)ステロイド紫斑
    　　(4)壊血病、Moller-Barlow病
    　　(5)IgA血管炎
    　　(6)薬剤性紫斑病(薬剤性血管炎)
    　3．単純性紫斑病
    　4．老人性紫斑病

    VII. 凝固・線溶異常による出血傾向
    　1．先天性凝固線溶異常症
    　　(1)血友病および類縁疾患
    　　(2)von Willebrand病
    　　(3)先天性線溶異常症
    　2．後天性凝固線溶異常症
    　　(1)循環抗凝固因子による出血傾向
    　　(2)DICと類縁疾患
    　　(3)ビタミンK欠乏症
    　　(4)その他の後天性凝固異常

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

V 血小板の異常

P.8 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al (ed) : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed, WHO, Lyon, 2008.
 
2) Buss DH, Cashell AW, O'Connor ML, et al : Occurrence, etiology, and clinical significance of extreme thrombocytosis : a study of 280 cases. Am J Med 96 : 247-253, 1994.
PubMed
3) Edahiro Y, Kurokawa Y, Morishita S, et al : Causes of Thrombocytosis : A Single-center Retrospective Study of 1,202 Patients. Intern Med 61 : 3323-3328, 2022.
 
4) Psaila B, Mead AJ : Single-cell approaches reveal novel cellular pathways for megakaryocyte and erythroid differentiation. Blood 133 : 1427-1435, 2019.
PubMed
5) Kowata S, Isogai S, Murai K, et al : Platelet demand modulates the type of intravascular protrusion of megakaryocytes in bone marrow. Thromb Haemost 112 : 743-756, 2014.
PubMed
6) Ishida Y, Ito T, Kuriya Si : Effects of c-mpl ligand on cytoplasmic maturation of murine megakaryocytes and on platelet production. J Histochem Cytochem 46 : 49-57, 1998.
PubMed
7) Ishibashi T, Shikama Y, Kimura H, et al : Thrombopoietic effects of interleukin-6 in long-term administration in mice. Exp Hematol 21 : 640-646, 1993.
PubMed
8) Ishida Y, Yano K, Ito T, et al : Purification of proplatelet formation (PPF) stimulating factor : thrombin/antithrombin III complex stimulates PPF of megakaryocytes in vitro and platelet production in vivo. Thromb Haemost 85 : 349-355, 2001.
PubMed
9) Stone RL, Nick AM, McNeish IA, et al : Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366 : 610-618, 2012.
PubMed
10) Xavier-Ferrucio J, Scanlon V, Li X, et al : Low iron promotes megakaryocytic commitment of megakaryocytic-erythroid progenitors in humans and mice. Blood 134 : 1547-1557, 2019.
PubMed
11) Ho KM, Yip CB, Duff O : Reactive thrombocytosis and risk of subsequent venous thromboembolism : a cohort study. J Thromb Haemost 10 : 1768-1774, 2012.
PubMed
12) Song AB, Kuter DJ, AI-Samkari H : Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia. Am J Hematol 95 : 1180-1186, 2020.
 
13) Bailey SE, Ukoumunne OC, Shephard EA, et al : Clinical relevance of thrombocytosis in primary care : a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. Br J Gen Pract 67 : e405-e413, 2017.
 
14) Tefferi A, Hoagland HC : Issues in the diagnosis and management of essential thrombocythemia. Mayo Clin Proc 69 : 651-655, 1994.
PubMed
15) Khoury JD, Solary E, Abla O, et al : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours : Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36 : 1703-1719, 2022.
PubMed
P.12 掲載の参考文献
1) Cines DB, Blanchette VS : Immune thrombocytopenic purpura. N Engl J Med 346 : 995-1008, 2002.
PubMed
2) 冨山佳昭 : 特発性血小板減少性紫斑病. 臨床血液 49 : 1298-1305, 2008.
 
3) Rodeghiero F, Stasi R, Gernsheimer T, et al : Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group. Blood 113 : 2386-2393, 2009.
 
4) 柏木浩和, ほか : 成人免疫性血小板減少症 (ITP) 診断参照ガイド 2023年版. 臨床血液 (10月号印刷中).
 
5) 藤沢康司 : 特発性血小板減少性紫斑病 (小児). 血液疾患診療ハンドブック-診療の手引きと臨床データ集-改訂版 (吉田彌太郎編), p557-571, 医薬ジャーナル社, 2009.
 
6) 石黒精, 森麻希子, 宮川義隆, ほか : 日本小児血液・がん学会 2022年 小児免疫性血小板減少症診療ガイドライン. 日本小児血液・がん学会誌 59 : 50-57, 2022.
 
P.16 掲載の参考文献
1) George JN, el-Harake MA, Raskob GE : Chronic idiopathic thrombocytopenic purpura. N Engl J Med 331 : 1207-1211, 1994.
PubMed
2) Cooper N, Ghanima W : Immune Thrombocytopenia. N Engl J Med 381 : 945-955, 2019.
PubMed
3) Vrbensky JR, Moore JE, Arnold DM, et al : The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia : a systematic review and meta-analysis of a diagnostic test. J Thromb Haemost 17 : 787-794, 2019.
PubMed
4) Kuwana M, Kaburaki J, Ikeda Y : Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 102 : 1393-1402, 1998.
PubMed
5) Kuwana M, Okazaki Y, Kaburaki J, et al : Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 168 : 3675-3682, 2002.
 
6) Zhang XL, Peng J, Sun JZ, et al : De novo induction of platelet-specific CD4 (+) CD25 (+) regulatory T cells from CD4 (+) CD25 (-) cells in patients with idiopathic thrombocytopenic purpura. Blood 113 : 2568-2577, 2009.
PubMed
7) Al-Samkari H, Rosovsky RP, Karp Leaf RS, et al : A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia. Blood Adv 4 : 9-18, 2020.
PubMed
8) Fabris F, Scandellari R, Ruzzon E, et al : Platelet-associated autoantibodies as detected by a solid-phase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood 103 : 4562-4564, 2004.
 
9) Mukai HY, Kojima H, Todokoro K, et al : Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost 76 : 675-678, 1996.
PubMed
10) Fujimura K, Kuwana M, Kurata Y, et al : Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP casesin Japan. Int J Hematol 81 : 162-168, 2005.
 
11) Stasi R, Pagano A, Stipa E, et al : Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98 : 952-957, 2001.
PubMed
12) Nomura S, Dan K, Hotta T, et al : Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 100 : 728-730, 2002.
PubMed
13) Bussel JB, Cheng G, Saleh MN, et al : Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357 : 2237-2247, 2007.
PubMed
14) Kuter DJ, Bussel JB, Lyons RM, et al : Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura : a double-blind randomised controlled trial. Lancet 371 : 395-403, 2008.
PubMed
15) Cooper N, Ghanima W, Hill QA, et al : Recent advances in understanding spleen tyrosine kinase (SYK) in human biology and disease, with a focus on fostamatinib. Platelets 34 : 2131751, 2023.
PubMed
16) Kuwana M, Ito T, Kowata S, et al : Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia : A phase 3, placebo-controlled, double-blind, parallel-group study. Br J Haematol 200 : 802-811, 2023.
 
17) Broome CM, McDonald V, Miyakawa Y, et al : Efficacy and safety of intravenous efgartigimod in adults with primary immune thrombocytopenia : results of a phase 3, multicenter, double-blinded, placebo-controlled, randomized clinical trial (ADVANCE IV). Blood 140 (Suppl 1) : 6-8, 2022.
 
18) Kuter DJ, Efraim M, Mayer J, et al : Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med 386 : 1421-1431, 2022.
PubMed
19) 柏木浩和 : 免疫性血小板減少症の病態と治療について. 臨床血液 64 : 397-405, 2023.
 
P.22 掲載の参考文献
1) 白幡聡, 石井榮一, 江口春彦, ほか : 小児特発性血小板減少性紫斑病-診断・治療・管理ガイドライン-. 日小血会誌 18 : 210-218, 2004.
 
2) 小児免疫性血小板減少症診療ガイドライン 2022年版 (日本小児血液・がん学会監), 診断と治療社, 2022.
 
3) 日本小児血液学会疾患登録委員会 : 平成21年度日本小児血液学会疾患登録集計報告. 日小血会誌 24 : 182-189, 2010.
 
4) Shirahata A, Fujisawa K, Ishii E, et al : A nationwide survey of newly diagnosed childhood idiopathic thrombocytopenic purpura in Japan. J Pediatr Hematol Oncol 31 : 27-32, 2009.
PubMed
5) Kitazawa J, Nakadate H, Matsubara K, et al : Favorable prognosis of vaccine-associated immune thrombocytopenia in children is correlated with young age at vaccination : Retrospective urvey of a nationwide disease registry. Int J Hematol 115 : 114-122, 2022.
 
6) Porcelijn L, Huiskes E, Oldert G, et al : Detection of platelet autoantibodies to identify immune thrombocytopenia : state of the art. Br J Haematol 182 : 423-426, 2018.
PubMed
7) Nishimoto T, Kuwana M : CD4 + CD25 + Foxp3 + regulatory T cells in the pathophysiology of immune thrombocytopenia. Semin Hematol 50 (Suppl 1) : S43-S49, 2013.
 
8) 笹原洋二, 國島伸治, 石黒精, ほか (日本小児血液・がん学会血小板委員会) : 先天性血小板減少症・異常症の診療ガイド. 日小児血がん会誌 58 : 253-262, 2021.
Medical*Online
9) Rodeghiero F, Stasi R, Gernsheimer T, et al : Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group. Blood 113 : 2386-2393, 2009.
 
10) Neunert C, Terrell DR, Arnold DM, et al : American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3 : 3829-3866, 2019.
PubMed
11) Schoettler ML, Graham D, Tao W, et al : Increasing observation rates in low-risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP). Pediatr Blood Cancer 64 : 10.1002/pbc.26303, 2017.
 
12) Heitink-Polle KM, Nijsten J, Boonacker CW, et al : Clinical and laboratory predictors of chronic immune thrombocytopenia in children : a systematic review and meta-analysis. Blood 124 : 3295-3307, 2014.
PubMed
13) Grainger JD, Locatelli F, Chotsampancharoen T, et al : Eltrombopag for children with chronic immune thrombocytopenia (PETIT2) : a randomised, multicentre, placebo-controlled trial. Lancet 386 : 1649-1658, 2015.
PubMed
14) Bussel JB, Buchanan GR, Nugent DJ, et al : A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood 118 : 28-36, 2011.
PubMed
15) Matsubara K, Takahashi Y, Hayakawa A, et al : Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab. Int J Hematol 99 : 429-436, 2014.
PubMed
P.29 掲載の参考文献
1) Cines DB, Blanchette VS : Immune thrombocytopenic purpura. N Engl J Med 346 : 995-1008, 2002.
PubMed
2) 冨山佳昭 : 特発性血小板減少性紫斑病. 臨床血液 49 : 1298-1305, 2008.
 
3) Rodeghiero F, Stasi R, Gernsheimer T, et al : Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group. Blood 113 : 2386-2393, 2009.
 
4) 柏木浩和, 桑名正隆, 村田満, ほか : 成人免疫性血小板減少症 (ITP) 診断参照ガイド 2023年版. 臨床血液 64 : 1245-1257, 2023.
 
5) Miltiadous O, Hou M, Bussel JB : Identifying and treating refractory ITP : difficulty in diagnosis and role of combination treatment. Blood 135 : 472-490, 2020.
PubMed
6) 柏木浩和, ほか : 成人特発性血小板減少性紫斑病治療の参照ガイド 2019 改訂版. 臨床血液 60 : 877-896, 2019.
 
7) Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al : Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97 : 2549-2554, 2001.
PubMed
8) Hato T, Shimada N, Kurata Y, et al : Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP : a nationwide study in Japan. Blood Adv 4 : 1648-1655, 2020.
PubMed
9) Kuter DJ : Novel therapies for immune thrombocytopenia. Br J Haematol 196 : 1311-1328, 2022.
PubMed
10) Kuwana M, Ito T, Kowata S, et al : Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia : A phase 3, placebo-controlled, double-blind, parallel-group study. Br J Haematol 200 : 802-811, 2023.
 
11) Broome C : Efgartigimod alfa for the treatment of primary immune thrombocytopenia. Ther Adv Hematol 14 : 20406207231172831, 2023.
PubMed
12) 冨山佳昭 : トロンボポエチン受容体作動薬による難治性ITPの治療. 臨床血液 52 : 627-632, 2011.
 
13) Al-Samkari H, Jiang D, Gernsheimer T, et al : Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim : A multicentre US study. Br J Haematol 197 : 359-366, 2022.
PubMed
14) Kuter DJ, Efraim M, Mayer J, et al : Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med 386 : 1421-1431, 2022.
PubMed
P.33 掲載の参考文献
1) Donato H : Neonatal thrombocytopenia : A review. I. Definitions, differential diagnosis, causes, immune thrombocytopenia. Arch Argent Pediatr 119 : e202-e214, 2021.
PubMed
2) Zdravic D, Yougbare I, Vadasz B, et al : Fetal and neonatal alloimmune thrombocytopenia. Semin Fetal Neonatal Med 21 : 19-27, 2016.
 
3) Ohto H, Miura S, Ariga H, et al : The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med 14 : 399-408, 2004.
PubMed
4) Curtis BR : Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol 171 : 671-682, 2015.
PubMed
5) Curtis BR, McFarland JG : Human platelet antigens - 2013. Vox Sang 106 : 93-102, 2014.
PubMed
6) Barg A, Bonstein L : New Horizons in Fetal and Neonatal Alloimmune Thrombocytopenia. Semin Thromb Hemost 49 : 402-408, 2023.
PubMed
7) de Vos TW, Winkelhorst D, de Haas M, et al : Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia. Transfus Apher Sci 59 : 102704, 2020.
PubMed
8) 森田庄治, 井上進, 花垣澄雄, ほか : 新生児同種免疫性血小板減少症 (NAIT) の抗体分析 : 1985～2005. 日本輸血細胞治療学会誌 52 : 678-683, 2006.
Medical*Online
9) 榎本隆行, 丸岡尚子, 花垣澄雄, ほか : 妊娠による血小板反応性抗体 (HLA 抗体とhuman platelet antigens 抗体) の産生 : 妊娠回数及び週齢と抗体陽性率の解析. 日本輸血学会誌 46 : 467-473, 2000.
 
10) 飯野美穂, 井上進, 二上由紀, ほか : 本邦における新生児血小板減少症の集計調査. 日本輸血細胞治療学会誌 56 : 508-514, 2010.
Medical*Online
11) Peterson JA, McFarland JG, Curtis BR, et al : Neonatal alloimmune thrombocytopenia : pathogenesis, diagnosis and management. Br J Haematol 161 : 3-14, 2013.
PubMed
12) 大井正, 酒井秀政, 村田乃理子, ほか : 発熱を契機に発見されたHLA-B7抗体陽性の新生児同種免疫性血小板減少症. 小児科臨床 71 : 1205-1211, 2018.
Medical*Online
13) 大西卓磨, 古市宗弘, 高村恭子, ほか : 血小板数が正常化するまでに2ヵ月を要した新生児同種免疫性血小板減少症. 日本小児科学会雑誌 121 : 101-105, 2017.
 
14) 峰研治, 關谷真一郎, 平林雅人, ほか : 抗HLA抗体による重症の新生児同種免疫性血小板減少症の双胎. 日本小児科学会雑誌 117 : 787-791, 2013.
 
15) 加賀元宗, 倉橋美佳, 中村理恵, ほか : 当院で経験した新生児同種免疫性血小板減少症と本邦既報116例の診断契機に関する検討. 共済医報 71 : 294-299, 2022.
 
16) 小林洋紀 : IV章 輸血検査と精度管理-H 血小板. スタンダード輸血検査テキスト 第3版 (認定輸血検査技師制度協議会カリキュラム委員会編). p146-152, 医歯薬出版, 2017.
 
P.39 掲載の参考文献
1) Ahmed I, Majeed A, Powell R : Heparin-induced thrombocytopenia : diagnosis and management update. Postgrad Med J 83 : 575-582, 2007.
PubMed
2) Warkentin TE, Kelton JG : Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 344 : 1286-1292, 2001.
PubMed
3) Warkentin TE, Kelton JG : Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 135 : 502-506, 2001.
PubMed
4) Roberge G, Tritschler T, MacGillivray C, et al : Persisting autoimmune heparin-induced thrombocytopenia after elective abdominal aortic aneurysm repair : a case report. J Thromb Thrombolysis 50 : 674-677, 2020.
PubMed
5) Mian H, Warkentin TE, Sheppard JI, et al : Autoimmune HIT due to apheresis catheter heparin flushes for stem cell harvesting before autotransplantation for myeloma. Blood 130 : 1679-1682, 2017.
PubMed
6) Greinacher A, Thiele T, Warkentin TE, et al : Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med 384 : 2092-2101, 2021.
PubMed
7) Zheng Y, Yu M, Podd A, et al : Critical role for mouse marginal zone B cells in PF4/heparin antibody production. Blood 121 : 3484-3492, 2013.
 
8) Arepally GM, Mayer IM : Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. Blood 98 : 1252-1254, 2001.
PubMed
9) Warkentin TE : Heparin-induced thrombocytopenia : pathogenesis and management. Br J Haematol 121 : 535-555, 2003.
PubMed
10) Watson H, Davidson S, Keeling D, et al : Guidelines on the diagnosis and management of heparin-induced thrombocytopenia : second edition. Br J Haematol 159 : 528-540, 2012.
PubMed
11) Warkentin TE, Greinacher A : Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies : a narrative review. Semin Thromb Hemost 49 : 621-633, 2023.
PubMed
12) Warkentin TE, Sheppard JI, Heels-Ansdell D, et al : Heparin-induced thrombocytopenia in medical surgical critical illness. Chest 144 : 848-858, 2013.
PubMed
13) Padmanabhan A, Jones CG, Curtis BR, et al : A Novel PF4-Dependent Platelet Activation Assay Identifies Patients Likely to Have Heparin-Induced Thrombocytopenia/Thrombosis. Chest 150 : 506-515, 2016.
PubMed
14) Warkentin TE, Kelton JG : A 14-year study of heparin-induced thrombocytopenia. Am J Med 101 : 502-507, 1996.
PubMed
15) Patriquin CJ, Laroche V, Selby R, et al : Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med 385 : 857-859, 2021.
PubMed
P.43 掲載の参考文献
1) George JN, Raskob GE, Shah SR, et al : Drug-induced thrombocytopenia : a systematic review of published case reports. Ann Intern Med 129 : 886-890, 1998.
PubMed
2) George JN, Aster RH : Drug-induced thrombocytopenia : pathogenesis, evaluation, and management. Hematology Am Soc Hematol Educ Program 2009 : 153-158, 2009.
PubMed
3) Aster RH, Bougie DW : Drug-induced immune thrombocytopenia. N Engl J Med 357 : 580-587, 2007.
PubMed
4) Najaoui A, Bakchoul T, Stoy J, et al : Autoantibody-mediated complement activation on platelets is a common finding in patients with immune thrombocytopenic purpura (ITP). Eur J Haematol 88 : 167-174, 2012.
PubMed
5) Peerschke EI, Andemariam B, Yin W, et al : Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura. Br J Haematol 148 : 638-645, 2010.
PubMed
6) McKenzie SE, Taylor SM, Malladi P, et al : The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets : a transgenic mouse model. J Immunol 162 : 4311-4318, 1999.
 
7) Curtis BR : Drug-induced immune thrombocytopenia : incidence, clinical features, laboratory testing, and pathogenic mechanisms. Immunohematology 30 : 55-65, 2014.
PubMed
8) Selleng K, Schutt A, Selleng S, et al : Studies of the anti-platelet factor 4/heparin immune response : adapting the enzyme-linked immunosorbent spot assay for detection of memory B cells against complex antigens. Transfusion 50 : 32-39, 2010.
PubMed
9) Warkentin TE : Laboratory diagnosis of heparin-induced thrombocytopenia. Int J Lab Hematol 41 (Suppl 1) : 15-25, 2019.
 
10) Bakchoul T, Marini I : Drug-associated thrombocytopenia. Hematology Am Soc Hematol Educ Program 2018 : 576-583, 2018.
PubMed
11) Marini I, Uzun G, Jamal K, et al : Treatment of drug-induced immune thrombocytopenias. Haematologica 107 : 1264-1277, 2022.
PubMed
12) Tvito A, Bakchoul T, Rowe JM, et al : Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment. Am J Hematol 90 : 675-678, 2015.
PubMed
13) Ray JB, Brereton WF, Nullet FR : Intravenous immune globulin for the treatment of presumed quinidine-induced thrombocytopenia. DICP 24 : 693-695, 1990.
PubMed
P.47 掲載の参考文献
1) Sadler JE : Pathophysiology of thrombotic thrombocytopenic purpura. Blood 130 : 1181-1188, 2017.
PubMed
2) 松本雅則, 宮川義隆, 小亀浩市, ほか : 血栓性血小板減少性紫斑病診療ガイド 2023. 臨床血液 64 : 445-460, 2023.
 
3) Terrell DR, Motto DG, Kremer Hovinga JA, et al : Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion 51 : 2237-2243, 2011.
PubMed
4) Sakai K, Kuwana M, Tanaka H, et al : HLA loci predisposing to immune TTP in Japanese : potential role of the shared ADAMTS13 peptide bound to different HLA-DR. Blood 135 : 2413-2419, 2020.
PubMed
5) Thomas MR, de Groot R, Scully MA, et al : Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura. EBioMedicine 2 : 942-952, 2015.
PubMed
6) Rock GA, Shumak KH, Buskard NA, et al : Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 325 : 393-397, 1991.
 
7) Sakai K, Wada H, Nakatsuka Y, et al : Characteristics Behaviors of Coagulation and Fibrinolysis Markers in Acquired Thrombotic Thrombocytopenic Purpura. J Intensive Care Med 36 : 436-442, 2021.
PubMed
8) Scully M, McDonald V, Cavenagh J, et al : A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 118 : 1746-1753, 2011.
PubMed
9) Miyakawa Y, Imada K, Ichinohe T, et al : Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy. Int J Hematol 104 : 228-235, 2016.
PubMed
10) Kayashima M, Sakai K, Harada K, et al : Strong association between insufficient plasma exchange and fatal outcomes in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura. Int J Hematol 114 : 415-423, 2021.
PubMed
11) Peyvandi F, Scully M, Kremer Hovinga JA, et al : Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 374 : 511-522, 2016.
PubMed
12) Scully M, Cataland SR, Peyvandi F, et al : Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med 380 : 335-346, 2019.
PubMed
13) Alwan F, Vendramin C, Vanhoorelbeke K, et al : Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura. Blood 130 : 466-471, 2017.
PubMed
14) Benhamou Y, Boelle PY, Baudin B, et al : Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost 13 : 293-302, 2015.
 
15) Schieppati F, Russo L, Marchetti M, et al : Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse : A multi-institutional study. Am J Hematol 95 : 953-959, 2020.
PubMed
P.51 掲載の参考文献
1) Kunishima S, Kojima T, Matsushita T, et al : Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome). Blood 97 : 1147-1149, 2001.
PubMed
2) Kunishima S, Saito H : Advances in the understanding of MYH9 disorders. Curr Opin Hematol 17 : 405-410, 2010.
PubMed
3) Pecci A, Ma X, Savoia A, et al : MYH9 : Structure, functions and role of non-muscle myosin IIA in human disease. Gene 664 : 152-167, 2018.
PubMed
4) Kunishima S, Matsushita T, Kojima T, et al : Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders : association of subcellular localization with MYH9 mutations. Lab Invest 83 : 115-122, 2003.
PubMed
5) Pecci A, Panza E, Pujol-Moix N, et al : Position of nonmuscle myosin heavy chain IIA (NMMHCIIA) mutations predicts the natural history of MYH9-related disease. Hum Mutat 29 : 409-417, 2008.
PubMed
6) Chang Y, Aurade F, Larbret F, et al : Proplatelet formation is regulated by the Rho/ROCK pathway. Blood 109 : 4229-4236, 2007.
PubMed
7) Chen Z, Naveiras O, Balduini A, et al : The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood 110 : 171-179, 2007.
PubMed
8) Sekine T, Konno M, Sasaki S, et al : Patients with Epstein-Fechtner syndromes owing to MYH9 R702 mutations develop progressive proteinuric renal disease. Kidney Int 78 : 207-214, 2010.
PubMed
9) Pecci A, Biino G, Fierro T, et al : Alteration of liver enzymes is a feature of the MYH9-related disease syndrome. PLoS One 7 : e35986, 2012.
PubMed
10) Kouno H, Kunishima S, Takebe J, et al : Measurement of immature platelet fraction is useful in the differential diagnosis of MYH9 disorders. Int J Lab Hematol 45 : 700-706, 2023.
PubMed
11) Hao J, Kada A, Kunishima S : Further classification of neutrophil non-muscle myosin heavy chain-IIA localization for efficient genetic diagnosis of MYH9 disorders. Ann Hematol 97 : 709-711, 2018.
PubMed
12) 國島伸治 : 先天性血小板減少症. 臨床血液 59 : 764-773, 2018
 
13) Eto K, Kunishima S : Linkage between the mechanisms of thrombocytopenia and thrombopoiesis. Blood 127 : 1234-1241, 2016.
PubMed
14) Pecci A, Gresele P, Klersy C, et al : Eltrombopag for the treatment of the inherited thrombocytopenia deriving from MYH9 mutations. Blood 116 : 5832-5837, 2010.
PubMed
15) Pecci A, Granata A, Fiore CE, et al : Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome). Nephrol Dial Transplant 23 : 2690-2692, 2008.
PubMed
P.55 掲載の参考文献
1) Bishop JF, Matthews JP, Yuen K, et al : The definition of refractoriness to platelet transfusions. Transfus Med 2 : 35-41, 1992.
PubMed
2) Schiffer CA, Anderson KC, Bennett CL, et al : Platelet transfusion for patients with cancer : clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 : 1519-1538, 2001.
 
3) Aster RH, Bougie DW : Drug-induced immune thrombocytopenia. N Engl J Med 357 : 580-587, 2007.
PubMed
4) 榎本隆行, 丸岡尚子, 花垣澄雄, ほか : 妊娠による血小板反応性抗体 (HLA抗体とhuman platelet antigens抗体) の産生 : 妊娠回数及び週齢と抗体陽性率の解析. 日本輸血学会雑誌 46 : 467-473, 2000.
Medical*Online
5) 永尾暢夫 : HLA適合血小板の供給. 日本輸血学会雑誌 43 : 30-33, 1997.
Medical*Online
6) Pappalardo PA, Secord AR, Quitevis P, et al : Platelet transfusion refractoriness associated with HPA-1a (PlA1) alloantibody without coexistent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 41 : 984-987, 2001.
PubMed
7) Fujiwara K, Shimano K, Tanaka H, et al : Application of bead array technology to simultaneous detection of human leucocyte antigen and human platelet antigen antibodies. Vox Sang 96 : 244-251, 2009.
PubMed
8) Mishima Y, Tsuno NH, Matsuhashi M, et al : Effects of universal vs bedside leukoreductions on the alloimmunization to platelets and the platelet transfusion refractoriness. Transfus Apher Sci 52 : 112-121, 2015.
PubMed
9) Schiffer CA, Bohlke K, Delaney M, et al : Platelet Transfusion for Patients With Cancer : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 36 : 283-299, 2018.
 
P.60 掲載の参考文献
1) Kyrle PA, Eichinger S : How I manage cyclic thrombocytopenia. Blood 137 : 178-184, 2021.
 
2) Go RS : Idiopathic cyclic thrombocytopenia. Blood Rev 19 : 53-59, 2005.
 
3) Steinbrecher O, Mitrovic M, Eischer L, et al : Clinical and laboratory characteristics of cyclic thrombocytopenia : an observational study. Haematologica 105 : e198-e201, 2020.
PubMed
4) Arnold DM, Nazy I, Clare R, et al : Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding : lessons from the McMaster ITP Registry. Blood Adv 1 : 2414-2420, 2017.
PubMed
5) Yanabu M, Nomura S, Fukuroi T, et al : Periodic production of antiplatelet autoantibody directed against GPIIIa in cyclic thrombocytopenia. Acta Haematol 89 : 155-159, 1993.
PubMed
6) Menitove JE, Pereira J, Hoffman R, et al : Cyclic thrombocytopenia of apparent autoimmune etiology. Blood 73 : 1561-1569, 1989.
PubMed
7) Fogarty PF, Stetler-Stevenson M, Pereira A, et al : Large granular lymphocytic proliferation-associated cyclic thrombocytopenia. Am J Hematol 79 : 334-336, 2005.
PubMed
8) Zhang H, Chien M, Hou Y, et al : Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3 and MPL mutations. Blood Adv 7 : 190-194, 2023.
PubMed
9) Fureder W, Mitterbauer G, Thalhammer R, et al : Clonal T cell-mediated cyclic thrombocytopenia. Br J Haematol 119 : 1059-1061, 2002.
PubMed
10) 栗原太郎, 住昌彦, 貝梅紘子, ほか : 月経周期に一致して血小板の低下と反跳性血小板増多を示した周期性血小板減少症. 臨床血液 58 : 243-245, 2017.
 
11) Mulroy E, Gleeson S, Chruka S : Danazol : an effective option in acquired amegakaryocytic thrombocytopaenic purpura. Case Rep Hematol 2015 : 171253, 2015.
 
12) Cheung E, Liebman HA : Thyroid disease in patients with immune thrombocytopenia. Hematol Oncol Clin North Am 23 : 1251-1260, 2009.
PubMed
13) Tauscher J, Siegel F, Petrides PE : Hydroxyurea-induced oscillations in twelve patients with polycythemia vera. Haematologica 95 : 1227-1229, 2010.
PubMed
14) Langlois GP, Arnold DM, Potts J, et al : Cyclic thrombocytopenia with statistically significant neutrophil oscillations. Clin Case Rep 6 : 1347-1352, 2018.
PubMed
15) 石川清, 内田俊樹 : 定期的な血小板数測定により診断に至った周期性血小板減少症. 臨床血液 64 : 66-68, 2023.
 
P.65 掲載の参考文献
1) Kunishima S, Kamiya T, Saito H : Genetic abnormalities of Bernard-Soulier syndrome. Int J Hematol 76 : 319-327, 2002.
PubMed
2) Savoia A, Kunishima S, De Rocco D, et al : Spectrum of the mutations in Bernard-Soulier syndrome. Hum Mutat 35 : 1033-1045, 2014.
PubMed
3) Cunningham JG, Meyer SC, Fox JE : The cytoplasmic domain of the α-subunit of glycoprotein (GP) Ib mediates attachment of the entire GP Ib-IX complex to the cytoskeleton and regulates von Willebrand factor-induced changes in cell morphology. J Biol Chem 271 : 11581-11587, 1996.
 
4) Balduini A, Malara A, Balduini CL, et al : Megakaryocytes derived from patients with the classical form of Bernard-Soulier syndrome show no ability to extend proplatelets in vitro. Platelets 22 : 308-311, 2011.
PubMed
5) Iwanaga M, Kunishima S, Ikeda S, et al : Vulnerable mutation Trp126→stop of glycoprotein IX in Japanese Bernard-Soulier syndrome. Eur J Haematol 60 : 264-266, 1998.
 
6) Kunishima S, Lopez JA, Kobayashi S, et al : Missense mutations of the glycoprotein (GP) Ib β gene impairing the GPIb α/β disulfide linkage in a family with giant platelet disorder. Blood 89 : 2404-2412, 1997.
 
7) Kunishima S, Yamada T, Hamaguchi M, et al : Bernard-Soulier syndrome due to GPIX W127X mutation in Japan is frequently misdiagnosed as idiopathic thrombocytopenic purpura. Int J Hematol 83 : 366-367, 2006.
PubMed
8) Andrews RK, Gardiner EE, Shen Y, et al : Glycoprotein Ib-IX-V. Int J Biochem Cell Biol 35 : 1170-1174, 2003.
PubMed
9) Kurokawa Y, Ishida F, Kamijo T, et al : A missense mutation (Tyr88 to Cys) in the platelet membrane glycoprotein Ibβ gene affects GPIb/IX complex expression-Bernard-Soulier syndrome in the homozygous form and giant platelets in the heterozygous form. Thromb Haemost 86 : 1249-1256, 2001.
 
10) Sivapalaratnam S, Westbury SK, Stephens JC, et al : Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia. Blood 129 : 520-524, 2017.
PubMed
11) Kunishima S, Imai T, Kobayashi R, et al : Bernard-Soulier syndrome caused by a hemizygous GPIbβ mutation and 22q11.2 deletion. Pediatr Int 55 : 434-437, 2013.
 
12) 國島伸治 : May-Hegglin 異常に代表されるMYH9異常症. 別冊日本臨牀血液症候群 (第3版) III」, p49-52, 日本臨牀社, 2023.
 
13) 國島伸治 : 先天性血小板減少症. 臨床血液 59 : 764-773, 2018.
 
14) Eto K, Kunishima S : Linkage between the mechanisms of thrombocytopenia and thrombopoiesis. Blood 127 : 1234-1241, 2016.
PubMed
15) Tefre KL, Ingerslev J, Sorensen B : Clinical benefit of recombinant factor VIIa in management of bleeds and surgery in two brothers suffering from the Bernard-Soulier syndrome. Haemophilia 15 : 281-284, 2009.
PubMed
16) Rieger C, Rank A, Fiegl M, et al : Allogeneic stem cell transplantation as a new treatment option for patients with severe Bernard-Soulier Syndrome. Thromb Haemost 95 : 190-191, 2006.
PubMed
P.70 掲載の参考文献
1) Germeshausen M, Ballmaier M : CAMT-MPL : congenital amegakaryocytic thrombocytopenia caused by MPL mutations-heterogeneity of a monogenic disorder-a comprehensive analysis of 56 patients. Haematologica 106 : 2439-2448, 2021.
PubMed
2) Ballmaier M, Germeshausen M : Congenital amegakaryocytic thrombocytopenia : clinical presentation, diagnosis, and treatment. Semin Thromb Hemost 37 : 673-681, 2011.
PubMed
3) Novotny JP, Kohler B, Max R, et al : Acquired Amegakaryocytic Thrombocytopenic Purpura Progressing into Aplastic Anemia. Prague Med Rep 118 : 147-155, 2017.
PubMed
4) Stoddart MT, Connor P, Germeshausen M, et al : Congenital amegakaryocytic thrombocytopenia (CAMT) presenting as severe pancytopenia in the first month of life. Pediatr Blood Cancer 60 : E94-E96, 2013.
PubMed
5) Greenwald HM, Sherman I : Congenital essential thrombocytopenia. Am J Dis Child 38 : 1242-1251, 1929.
 
6) Balduini CL : The name counts : the case of 'congenital amegakaryocytic thrombocytopenia'. Haematologica 108 : 1216-1219, 2023.
PubMed
7) Geddis AE : Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer 57 : 199-203, 2011.
PubMed
8) Ballmaier M, Germeshausen M : Advances in the understanding of congenital amegakaryocytic thrombocytopenia. Br J Haematol 146 : 3-16, 2009.
PubMed
9) Pecci A, Ragab I, Bozzi V, et al : Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim. EMBO Mol Med 10 : 63-75, 2018.
PubMed
10) Germeshausen M, Ancliff P, Estrada J, et al : MECOM-associated syndrome : a heterogeneous inherited bone marrow failure syndrome with amegakaryocytic thrombocytopenia. Blood Adv 2 : 586-596, 2018.
PubMed
11) Cowan J, Parikh T, Waghela R, et al : Thrombocytopenia with absent Radii (TAR) Syndrome without significant thrombocytopenia. Cureus 12 : e10557, 2020.
PubMed
12) Ichikawa T, Shimojima Y, Otuki T, et al : Acquired Amegakaryocytic Thrombocytopenia in Adult-onset Still's Disease : Successful Combination Therapy with Tocilizumab and Cyclosporine. Intern Med 58 : 3473-3478, 2019.
PubMed
13) Al-Qahtani FS : Congenital amegakaryocytic thrombocytopenia : a brief review of the literature. Clin Med Insights Pathol 3 : 25-30, 2010.
PubMed
14) Cancio M, Hebert K, Kim S, et al : Outcomes in hematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia. Transplant Cell Ther 28 : 101.e1-101.e6, 2022.
 
15) Woods G, Bajwa RP, Rose MJ : Reduced intensity transplantation for congenital amegakaryocytic thrombocytopenia : report of a case and review of the literature. Pediatr Transplant 18 : E31-E34, 2014.
PubMed
P.75 掲載の参考文献
1) Beckman Coulter web site : 血球計数測定とコールター原理 [https://www.beckmancoulter.co.jp/dx/blog/blog_detail_00055/]
 
2) Gowland E, Kay HE, Spillman JC, et al : Agglutination of platelets by a serum factor in the presence of EDTA. J Clin Pathol 22 : 460-464, 1969.
PubMed
3) Sweeney JD, Holme S, Heaton WA, et al : Pseudothrombocytopenia in plateletpheresis donors. Transfusion 35 : 46-49, 1995.
PubMed
4) Silvestri F, Virgolini L, Savignano C, et al : Incidence and diagnosis of EDTA-dependent pseudothrombocytopenia in a consecutive outpatient population referred for isolated thrombocytopenia. Vox Sang 68 : 35-39, 1995.
 
5) Froom P, Barak M : Prevalence and course of pseudothrombocytopenia in outpatients. Clin Chem Lab Med 49 : 111-114, 2011.
PubMed
6) Bartels PCM, Schoorl M, Lombarts AJ : Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia. Scand J Clin Lab Invest 57 : 629-636, 1997.
 
7) Garcia Suarez J, Merino JL, Rodriguez M, et al : Pseudothrombocytopenia : Incidence, causes and methods of detection. Sangre (Barc) 36 : 197-200, 1991.
PubMed
8) Xiao Y, Yu S, Xu Y : The Prevalence and Biochemical Profiles of EDTA-Dependent Pseudothrombocytopenia in a Generally Healthy Population. Acta Haematol 134 : 177-180, 2015.
 
9) Onder O, Weinstein A, Hoyer LW : Pseudothrombocytopenia caused by platelet agglutinins that are reactive in blood anticoagulated with chelating agents. Blood 56 : 177-182, 1980.
PubMed
10) 熊本忠史, 山本初実 : EDTA依存性偽性血小板減少症の1小児例-免疫学的発症機序に関する考察-. 日本小児血液学会誌 8 : 230-233, 1994.
 
11) Lardinois B, Favresse J, Chatelain B, et al : Pseudothrombocytopenia-A Review on Causes, Occurrence and Clinical Implications. J Clin Med 10 : 594, 2021.
PubMed
12) Hoffmeister KM, Felbinger TW, Falet H, et al : The clearance mechanism of chilled blood platelets. Cell 112 : 87-97, 2003.
PubMed
13) 倉田義之, 林悟, 城崎潔 : 血小板寒冷凝集素により偽性血小板減少症を呈した4例. 臨床血液 47 : 781-786, 2006.
 
14) Sakurai S, Shiojima I, Tanigawa T, et al : Aminoglycosides prevent and dissociate the aggregation of platelets in patients with EDTA-dependent pseudothrombocytopenia. Br J Haematol 99 : 817-823, 1997.
PubMed
15) 土屋直道, 松尾収二 : EDTA依存性偽性血小板減少症における血小板数推移パターンおよび抗凝固剤としての硫酸マグネシウムの有用性. Sysmex Journal Web 20 : 54-61, 2019. [https://www.sysmex.co.jp/products_solutions/library/journal/vol20_no3/bfvlfm000000cj8s-att/Vol20_3_04.pdf]
 
P.79 掲載の参考文献
1) Raccuglia G : Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med 51 : 818-828, 1971.
PubMed
2) 一色郁子, 池田康夫 : α-Storage pool病 (Gray platelet症候群). 別冊日本臨牀血液症候群 (II), p350-351, 日本臨牀社, 1998.
 
3) Gunay-Aygun M, Zivony-Elboum Y, Gumruk F, et al : Gray platelet syndrome : natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 116 : 4990-5001, 2010.
PubMed
4) Mori K, Suzuki S, Sugai K : Electron microscopic and functional studies on platelets in gray platelet syndrome. Tohoku J Exp Med 143 : 261-287, 1984.
PubMed
5) Nurden AT, Nurden P : The gray platelet syndrome : clinical spectrum of the disease. Blood Rev 21 : 21-36, 2007.
PubMed
6) Albers CA, Cvejic A, Favier R, et al : Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet 43 : 735-737, 2011.
PubMed
7) Guerrero JA, Bennett C, van der Weyden L, et al : Gray platelet syndrome : proinflammatory megakaryocytes and α-granule loss cause myelofibrosis and confer metastasis resistance in mice. Blood 124 : 3624-3635, 2014.
 
8) Tubman VN, Levine JE, Campagna DR, et al : X-linked gray platelet syndrome due to a GATA1 Arg216Gln mutation. Blood 109 : 3297-3299, 2007.
PubMed
9) Wijgaerts A, Wittevrongel C, Thys C, et al : The transcription factor GATA1 regulates NBEAL2 expression through a long-distance enhancer. Haematologica 102 : 695-706, 2017.
PubMed
10) Collins JH, Mayer L, Guerrero Lopez JA : Immune dysregulation, autoimmunity, and granule defects in gray platelet syndrome. J Thromb Haemost 21 : 1409-1419, 2023.
PubMed
11) Falik-Zaccai TC, Anikster Y, Rivera CE, et al : A new genetic isolate of gray platelet syndrome (GPS) : clinical, cellular, and hematologic characteristics. Mol Genet Metab 74 : 303-313, 2001.
PubMed
12) Breton-Gorius J, Vainchenker W, Nurden A, et al : Defective alpha-granule production in megakaryocytes from gray platelet syndrome : ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol 102 : 10-19, 1981.
PubMed
13) White JG : Ultrastructural studies of the gray platelet syndrome. Am J Pathol 95 : 445-462, 1979.
PubMed
P.82 掲載の参考文献
1) Dupuis A, Bordet JC, Eckly A, et al : Platelet δ-Storage Pool Disease : An Update. J Clin Med 9 : 2508, 2020.
 
2) Weiss HJ, Chervenick PA, Zalusky R, et al : A familialdefect in platelet function associated with imapired release of adenosine diphosphate. N Engl J Med 281 : 1264-1270, 1969.
 
3) Holmsen H, Weiss HJ : Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia- "storage pool disease". Blood 39 : 197-209, 1972.
PubMed
4) Nieuwenhuis HK, Akkerman JW, Sixma JJ : Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency : studies on one hundred six patients. Blood 70 : 620-623, 1987.
PubMed
5) Latger-Cannard V, Philippe C, Bouquet A, et al : Haematological spectrum and genotypephenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders. Orphanet J Rare Dis 11 : 49, 2016.
PubMed
6) Bolton-Maggs PH, Chalmers EA, Collins PW, et al : A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 135 : 603-633, 2006.
 
7) Weiss HJ, Ames RP : Ultrastructural findings in storage pool disease and aspirin-like defects of platelets. Am J Pathol 71 : 447-466, 1973.
PubMed
8) Sandrock K, Zieger B : Current Strategies in Diagnosis of Inherited Storage Pool Defects. Transfus Med Hemother 37 : 248-258, 2010.
PubMed
9) Sladky JL, Klima J, Grooms L, et al : The PFA-100 does not predict delta-granule platelet storage pool deficiencies. Haemophilia 18 : 626-629, 2012.
 
10) Wall JE, Buijs-Wilts M, Arnold JT, et al : A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br J Haematol 89 : 380-385, 1995.
PubMed
11) Gordon N, Thom J, Cole C, et al : Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br J Haematol 89 : 117-123, 1995.
PubMed
12) Castaman G, Rodeghiero F : Consistency of responses to separate desmopressin infusions in patients with storage pool disease and isolated prolonged bleeding time. Thromb Res 69 : 407-412, 1993.
PubMed
13) Nieuwenhuis HK, Sixma JJ : 1-Desamino-8-D-arginine vasopressin (desmopressin) shortens the bleeding time in storage pool deficiency. Ann Intern Med 108 : 65-67, 1988.
PubMed
14) Franchini M : The use of recombinant activated factor VII in platelet disorders : a critical review of the literature. Blood Transfus 7 : 24-28, 2009.
PubMed
P.87 掲載の参考文献
1) Di Minno G, Zotz RB, d'Oiron R, et al : The international, prospective Glanzmann Thrombasthenia Registry : treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia. Haematologica 100 : 1031-1037, 2015.
PubMed
2) Botero JP, Lee K, Branchford BR, et al : Glanzmann thrombasthenia : genetic basis and clinical correlates. Haematologica 105 : 888-894, 2020.
PubMed
3) Nurden P, Stritt S, Favier R, et al : Inherited platelet diseases with normal platelet count : phenotypes, genotypes and diagnostic strategy. Haematologica 106 : 337-350, 2021.
PubMed
4) Nurden A : Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia : Can It Guide Current and Future Therapies? J Blood Med 12 : 581-599, 2021.
PubMed
5) Nurden AT, Fiore M, Nurden P, et al : Glanzmann thrombasthenia : a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 118 : 5996-6005, 2011.
PubMed
6) George JN, Caen JP, Nurden AT : Glanzmann's thrombasthenia : the spectrum of clinical disease. Blood 75 : 1383-1395, 1990.
PubMed
7) Fiore M, Sentilhes L, d'Oiron R : How I manage pregnancy in women with Glanzmann thrombasthenia. Blood 139 : 2632-2641, 2022.
 
8) Grainger JD, Thachil J, Will AM : How we treat the platelet glycoprotein defects ; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. Br J Haematol 182 : 621-632, 2018.
PubMed
9) Gresele P ; Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis : Diagnosis of inherited platelet function disorders : guidance from the SSC of the ISTH. J Thromb Haemost 13 : 314-322, 2015.
PubMed
10) Fiore M, d'Oiron R, Pillois X, et al : Anti-αIIb β3 immunization in Glanzmann thrombasthenia : review of literature and treatment recommendations. Br J Haematol 181 : 173-182, 2018.
 
P.90 掲載の参考文献
1) Nurden P, Stritt S, Favier R, et al : Inherited platelet diseases with normal platelet count : phenotypes, genotypes and diagnostic strategy. Haematologica 106 : 337-350, 2021
PubMed
2) George JN, Caen JP, Nurden AT : Glanzmann's thrombasthenia : the spectrum of clinical disease. Blood 75 : 1383-1395, 1990.
PubMed
3) Nurden A : Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia : Can It Guide Current and Future Therapies? J Blood Med 12 : 581-599, 2021.
PubMed
4) Botero JP, Lee K, Branchford BR, et al : Glanzmann thrombasthenia : genetic basis and clinical correlates. Haematologica 105 : 888-894, 2020.
PubMed
5) Nurden AT, Fiore M, Nurden P, et al : Glanzmann thrombasthenia : a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 118 : 5996-6005, 2011.
PubMed
6) Kunishima S, Kashiwagi H, Otsu M, et al : Heterozygous ITGA2B R995W mutation inducing constitutive activation of the αIIbβ3 receptor affects proplatelet formation and causes congenital macrothrombocytopenia. Blood 117 : 5479-5484, 2011.
 
7) Canault M, Ghalloussi D, Grosdidier C, et al : Human CalDAG-GEFI gene (RASGRP2) mutation affects platelet function and causes severe bleeding. J Exp Med 211 : 1349-1362, 2014.
PubMed
8) Jurk K, Schulz AS, Kehrel BE, et al : Novel integrin-dependent platelet malfunction in siblings with leukocyte adhesion deficiency-III (LAD-III) caused by a point mutation in FERMT3. Thromb Haemost 103 : 1053-1064, 2010.
PubMed
9) Gresele P ; Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis : Diagnosis of inherited platelet function disorders : guidance from the SSC of the ISTH. J Thromb Haemost 13 : 314-322, 2015.
PubMed
10) Grainger JD, Thachil J, Will AM : How we treat the platelet glycoprotein defects ; Glanzmann thrombasthenia and Bernard Soulier syndrome in children and adults. Br J Haematol 182 : 621-632, 2018.
PubMed
11) Fiore M, d'Oiron R, Pillois X, et al : Anti-αIIb β3 immunization in Glanzmann thrombasthenia : review of literature and treatment recommendations. Br J Haematol 181 : 173-182, 2018.
 
P.95 掲載の参考文献
1) 日本呼吸器学会監修・難治性びまん性肺疾患診療の手引き作成委員会編集 : 難治性びまん性肺疾患診療の手引き, 第3章, p72-98, 南江堂, 2017.
 
2) Velazquez-Diaz P, Nakajima E, Sorkhdini P, et al : Hermansky-Pudlak Syndrome and Lung Disease : Pathogenesis and Therapeutics. Front Pharmacol 12 : 644671, 2021.
PubMed
3) 海老名雅仁, 桑野和善 : 稀少難治性びまん性肺疾患部会報告 : Hermansky-Pudlak症候群関連間質性肺炎に関する疫学調査. 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」平成26年度報告書, p53-56, 2015.
 
4) Adam MP, MirZaa GM, Pagon RA, et al (ed) : Hermansky-Pudlak Syndrome. GeneReviews, University of Washington, Seattle, 1993-2023.
 
5) O'Brien K, Troendle J, Gochuico BR, et al : Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 103 : 128-134, 2011.
PubMed
6) Meyer KC, Decker CA : Role of pirfenidone in the management of pulmonary fibrosis. Ther Clin Risk Manag 13 : 427-437, 2017.
PubMed
7) O'Brien KJ, Introne WJ, Akal O, et al : Prolonged treatment with open-label pirfenidone in Hermansky-Pudlak syndrome pulmonary fibrosis. Mol Genet Metab 125 : 168-173, 2018.
PubMed
8) El-Chemaly S, O'Brien KJ, Nathan SD, et al : Clinical management and outcomes of patients with Hermansky-Pudlak syndrome pulmonary fibrosis evaluated for lung transplantation. PLoS One 13 : e0194193, 2018.
PubMed
9) El-Chemaly S, Young LR : Hermansky-Pudlak Syndrome. Clin Chest Med 37 : 505-511, 2016.
PubMed
P.99 掲載の参考文献
1) Weiss HJ, Vicic WJ, Lages BA, et al : Isolated deficiency of platelet procoagulant activity. Am J Med 67 : 206-213, 1979.
PubMed
2) Toti F, Satta N, Fressinaud E, et al : Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 87 : 1409-1415, 1996.
PubMed
3) Ahmad SS, Rawala-Sheikh R, Ashby B, et al : Platelet receptor-mediated factor X activation by factor IXa. High-affinity factor IXa receptors-induced by factor VIII are deficient on platelets in Scott syndrome. J Clin Invest 84 : 824-828, 1989
PubMed
4) Parry DH, Giddings JC, Bloom AL : Familial haemostatic defect associated with reduced prothrombin consumption. Br J Haematol 44 : 323-334, 1980.
PubMed
5) Halliez M, Fouassier M, Robillard N, et al : Detection of phosphatidyl serine on activated platelets' surface by flow cytometry in whole blood : a simpler test for the diagnosis of Scott syndrome. Br J Haematol 171 : 290-292, 2015.
 
6) Flores-Nascimento MC, Orsi FL, Yokoyama AP, et al : Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagul Fibrinolysis 23 : 75-77, 2012.
PubMed
7) Bouchaib AE, Balde MA, Babahabib A, et al : [Scott's syndrome and pregnancy : about a case]. Pan Afr Med J 44 : 151, 2023.
 
8) Munnix IC, Harmsma M, Giddings JC, et al : Store-mediated calcium entry in the regulation of phosphatidylserine exposure in blood cells from Scott patients. Thromb Haemost 89 : 687-695, 2003.
PubMed
9) Percy CL, Macartney N, Pollard B, et al : Laboratory monitoring of Scott Syndrome. Br J Haematol 149 : 803, 2010.
PubMed
10) Boisseau P, Bene MC, Besnard T, et al : A new mutation of ANO6 in two familial cases of Scott syndrome. Br J Haematol 180 : 750-752, 2018.
PubMed
11) Castoldi E, Collins PW, Williamson PL, et al : Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndrome. Blood 117 : 4399-4400, 2011.
 
12) Suzuki J, Umeda M, Sims PJ, et al : Calcium-dependent phospholipid scrambling by TMEM16F. Nature 468 : 834-838, 2010.
PubMed
13) Reininger AJ, Heijnen HF, Schumann H, et al : Mechanism of platelet adhesion to von Willebrand factor and microparticle formation under high shear stress. Blood 107 : 3537-3545, 2006.
PubMed
14) Satta N, Toti F, Fressinaud E, et al : Scott syndrome : an inherited defect of the procoagulant activity of platelets. Platelets 8 : 117-124, 1997.
PubMed
15) Rosing J, Bevers EM, Comfurius P, et al : Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood 65 : 1557-1561, 1985.
PubMed
16) Sims PJ, Wiedmer T, Esmon CT, et al : Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome : an isolated defect in platelet procoagulant activity. J Biol Chem 264 : 17049-17057, 1989.
PubMed
P.104 掲載の参考文献
1) Song WJ, Sullivan MG, Legare RD, et al : Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23 : 166-175, 1999.
PubMed
2) Schlegelberger B, Heller PG : RUNX1 deficiency (familial platelet disorder with predisposition to myeloid leukemia, FPDMM). Semin Hematol 54 : 75-80, 2017.
PubMed
3) Khoury JD, Solary E, Abla O, et al : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours : Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 36 : 1703-1719, 2022.
PubMed
4) Simon L, Spinella JF, Yao CY, et al : High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. Blood 135 : 1882-1886, 2020.
PubMed
5) Sood R, Kamikubo Y, Liu P : Role of RUNX1 in hematological malignancies. Blood 129 : 2070-2082, 2017.
PubMed
6) Yoshimi A, Toya T, Kawazu M, et al : Recurrent CDC25C mutations drive malignant transformation in FPD/AML. Nat Commun 5 : 4770, 2014.
PubMed
7) Brown AL, Arts P, Carmichael CL, et al : RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML. Blood Adv 4 : 1131-1144, 2020.
 
8) Kanagal-Shamanna R, Loghavi S, DiNardo CD, et al : Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102 : 1661-1670, 2017.
PubMed
9) Brown AL, Churpek JE, Malcovati L, et al : Recognition of familial myeloid neoplasia in adults. Semin Hematol 54 : 60-68, 2017.
PubMed
10) Iizuka H, Kagoya Y, Kataoka K, et al : Targeted gene correction of RUNX1 in-induced pluripotent stem cells derived from familial platelet disorder with propensity to myeloid malignancy restores normal megakaryopoiesis. Exp Hematol 43 : 849-857, 2015.
PubMed
11) Krutein MC, Hart MR, Anderson DJ, et al : Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation. Blood Adv 5 : 687-699, 2021.
PubMed
P.110 掲載の参考文献
1) 金子誠, 矢冨裕 : 血小板機能異常症の診断と対応. 日本血栓止血学会誌 20 : 487-494, 2009.
 
2) 柏木浩和 : 後天性血小板機能異常症. 日本血栓止血学会誌 29 : 620-624, 2018.
 
3) Brennan Y, Levade M, Ward CM : Acquired platelet function disorders. Thromb Res 196 : 561-568, 2020.
PubMed
4) Konkle BA : Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program 2011 : 391-396, 2011.
PubMed
5) Scharf RE : Drugs that affect platelet function. Semin Thromb Hemost 38 : 865-883, 2012.
PubMed
6) Nagalla S, Sarode R : Role of Platelet Transfusion in the Reversal of Anti-Platelet Therapy. Transfus Med Rev 33 : 92-97, 2019.
PubMed
7) 新家俊郎, 辻田裕昭 : 抗血小板療法の実際. 日本血栓止血学会誌 30 : 93-99, 2019.
 
8) 冨山佳昭 : P2Y12受容体に関する遺伝子関連検査. 日本血栓止血学会誌 23 : 450-456, 2012.
 
9) Giannitsis E, Katus HA : Antiplatelet therapy - ticagrelor. Hamostaseologie 32 : 177-185, 2012.
PubMed
10) Bannow BS, Konkle BA : How I approach bleeding in hospitalized patients. Blood 142 : 761-768, 2023.
 
11) Yin Z, Zou Y, Wang D, et al : Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease. Cell Death Discov 8 : 119, 2022.
PubMed
12) Baker RI, O'Donnell JS : How I treat bleeding disorder of unknown cause. Blood 138 : 1795-1804,
 
13) 中川秀紀, 辻陽介, 藤城光弘 : [内視鏡データリファレンスブック 2022] 消化器内視鏡全般抗血栓薬服用患者における内視鏡検査および治療. 消化器内視鏡 34 (4 月増大号) : 497-503, 2022.
 
14) 藤本一眞, 藤城光弘, 加藤元嗣, ほか : 抗血栓薬服用者に対する消化器内視鏡診療ガイドライン. 日本消火器内視鏡学会雑誌 54 : 2075-2102, 2012.
 
2021.
 
P.115 掲載の参考文献
1) 血栓止血学会用語集 (大分類「血小板」) 血小板無力症/Glanzmann Thrombasthenia : http://jsth.medical-words.jp/main-category/platelet/page/2/
 
2) WE Glanzmann : Hereditare hamorrhagische Thrombasthenie. Ein Beitrag zur Pathologie der Blutplattchen. Jahrbuch fur Kinderheilkunde 88 : 1-42, 113-141, 1918.
 
3) Mathews N, Rivard GE, Bonnefoy A : Glanzmann Thrombasthenia : Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies. J Blood Med 12 : 449-463, 2021.
PubMed
4) Tholouli E, Hay CR, O'Gorman P, et al : Acquired Glanzmann's thrombasthenia without thrombocytopenia : a severe acquired autoimmune bleeding disorder. Br J Haematol 127 : 209-213, 2004.
PubMed
5) Nurden AT : Acquired Glanzmann thrombasthenia : From antibodies to anti-platelet drugs. Blood Rev 36 : 10-22, 2019.
PubMed
6) 冨山佳昭 : 抗血小板抗体の検出とその臨床的意義. 日本輸血細胞治療学会誌 64 : 681-687, 2018.
Medical*Online
7) Fuse I, Higuchi W, Narita M, et al : Overproduction of antiplatelet antibody against glycoprotein IIb after splenectomy in a patient with Evans syndrome resulting in acquired thrombasthenia. Acta Haematol 99 : 83-88, 1998.
 
8) Bacci M, Ferretti A, Marchetti M, et al : Autoimmune disorders of platelet function : systematic review of cases of acquired Glanzmann thrombasthenia and acquired delta storage pool disease. Blood Transfus 20 : 420-432, 2022.
PubMed
9) Constantinescu-Bercu A, McCann S, Hmaid A, et al : Acquired Glanzmann's thrombasthenia with IgG and IgA against activated αIIbβ3. Br J Haematol. 202 : e58-e61, 2023.
 
10) Rajpurkar M, Chitlur M, Recht M, et al : Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia : a review of the literature. Haemophilia 20 : 464-471, 2014.
PubMed
11) Poon MC : The Use of Recombinant Activated Factor VII in Patients with Glanzmann's Thrombasthenia. Thromb Haemost 121 : 332-340, 2021.
PubMed
12) 桑原光弘 : Factor VIIa製剤の過去・現在・未来. 日本血栓止血学会誌 25 : 475-481, 2014.
 
13) Thomas RV, Bessos H, Turner ML, et al : The successful use of plasma exchange and immunosuppression in the management of acquired Glanzmann's thrombasthenia. Br J Haematol 119 : 878-880, 2002.
PubMed
14) Ito K, Yoshida H, Hatoyama H, et al : Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann's thrombasthenia and multiple anti-platelet antibodies. Vox Sang 61 : 40-46, 1991.
PubMed
15) Padate B, Mansukhani D, Jijina F, et al : Acquired Glanzmann thrombasthenia : a rare disorder. J Hematopathol 14 : 145-150, 2021.
 

VI 血管障害による出血傾向

P.122 掲載の参考文献
1) Kritharis A, Al-Samkari H, Kuter DJ : Hereditary hemorrhagic telangiectasia : diagnosis and management from the hematologist's perspective. Haematologica 103 : 1433-1443, 2018.
PubMed
2) McDonald J, Bayrak-Toydemir P, Pyeritz RE : Hereditary hemorrhagic telangiectasia : an overview of diagnosis, management, and pathogenesis. Genet Med 13 : 607-616, 2011.
PubMed
3) Dupuis-Girod S, Bailly S, Plauchu H : Hereditary hemorrhagic telangiectasia : from molecular biology to patient care. J Thromb Haemost 8 : 1447-1456, 2010.
PubMed
4) Grand'Maison A : Hereditary hemorrhagic telangiectasia. CMAJ 180 : 833-835, 2009.
PubMed
5) McAllister KA, Grogg KM, Johnson DW, et al : Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 8 : 345-351, 1994.
PubMed
6) Johnson DW, Berg JN, Baldwin MA, et al : Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 13 : 189-195, 1996.
PubMed
7) Prigoda NL, Savas S, Abdalla SA, et al : Hereditary haemorrhagic telangiectasia : mutation detection, test sensitivity and novel mutations. J Med Genet 43 : 722-728, 2006.
PubMed
8) Shovlin CL, Guttmacher AE, Buscarini E, et al : Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 91 : 66-67, 2000.
PubMed
9) Irani F, Kasmani R : Hereditary hemorrhagic telangiectasia : fatigue and dyspnea. CMAJ 180 : 839, 2009.
PubMed
10) Easey AJ, Wallace GM, Hughes JM, et al : Should asymptomatic patients with hereditary haemorrhagic telangiectasia (HHT) be screened for cerebral vascular malformations? Data from 22,061 years of HHT patient life. J Neurol Neurosurg Psychiatry 74 : 743-748, 2003.
 
11) Curie A, Lesca G, Cottin V, et al : Long-term follow-up in 12 children with pulmonary arteriovenous malformations : confirmation of hereditary hemorrhagic telangiectasia in all cases. J Pediatr 151 : 299-306, 2007.
 
12) Al-Samkari H, Kritharis A, Rodriguez-Lopez JM, et al : Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia. J Intern Med 285 : 223-231, 2019.
PubMed
P.128 掲載の参考文献
1) Malfait F, Francomano C, Byers P, et al : The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 175 : 8-26, 2017.
PubMed
2) Ehlers-Danlos Syndrome, Classic Type Synonym : Ehlers-Danlos Syndrome, Classical Type. Includes : Ehlers-Danlos Syndrome Type I, Ehlers-Danlos Syndrome Type II (ed by Malfait F, Wenstrup R, Paepe AD, et al), GeneReviews [Internet]. Seattle (WA) : University of Washington, Seattle ; 1993-. Initial Posting : September 2, 1999 ; Last Update : May 3, 2011.
 
3) Ehlers-Danlos Syndrome, Hypermobility Type Synonyms : EDS Hypermobility Type, EDS Type III, Ehlers-Danlos Syndrome Type III (ed by Levy HP, Pagon RA, Bird TD, et al), GeneReviews [Internet]. Seattle (WA) : University of Washington, Seattle ; 1993-. Initial Posting : October 22, 2004 ; Last Update : September 13, 2012.
 
4) Ehlers-Danlos Syndrome Type IV Synonyms : EDS Type IV ; Ehlers-Danlos Syndrome, Vascular Type (ed by Pepin MG, Byers PH, Bagon RA, et al), GeneReviews [Internet]. Seattle (WA) : University of Washington, Seattle ; 1993-. Initial Posting : September 2, 1999 ; Last Update : May 3, 2011.
 
5) Malfait F, Wenstrup RJ, De Paepe A : Clinical and genetic aspects of Ehlers-Danlos syndrome, classic type. Genet Med 12 : 597-605, 2010.
PubMed
6) Beighton P, De Paepe A, Steinmann B, et al : Ehlers-Danlos syndromes : revised nosology, Villefranche, 1997. Ehlers- Danlos National Foundation (USA) and Ehlers-Danlos Support Group (UK). Am J Med Genet 77 : 31-37, 1998.
PubMed
7) Leistritz DF, Pepin MG, Schwarze U, et al : COL3A1 haploinsufficiency results in EDS type IV with delayed onset of complications and longer life span when compared to missense and splicesite mutations. Washington, DC : American Society of Human Genetics 60th Annual Meeting, 2010.
 
8) Schwarze U, Schievink WI, Petty E, et al : Haploinsufficiency for one COL3A1 allele of type III procollagen results in a phenotype similar to the vascular form of Ehlers-Danlos syndrome, Ehlers-Danlos syndrome type IV. Am J Hum Genet 69 : 989-1001, 2001.
 
9) Miyake N, Kosho T, Mizumoto S, et al : Loss-of-function mutations of CHST14 in a new type of Ehlers-Danlos syndrome. Hum Mutat 31 : 966-974, 2010.
 
P.130 掲載の参考文献
1) Levin MB, Pinkus H : Autosensitivity to desoxyribonucleic acid (DNA). Report of a case with inflammatory skin lesions controlled by chloroquine. N Engl J Med 264 : 533-537, 1961.
PubMed
2) 河野照隆 : DNA自己感作性紫斑病. 感染・炎症・免疫 16 : 132-137, 1986.
 
3) Brauner F, Brenner W, Gschnait F : Autosensitization to DNA. Acta Derm Venereol 60 : 345-348, 1980.
PubMed
4) Rodriguez Fernandez JM, Linares Ruiz MS : DNA-autosensitivity : report of two cases (author's transl). Sangre (Barc) 26 : 114-122, 1981.
 
5) Sugai S, Konda S, Yamamoto M, et al : A case of DNA autosensitivity. Arerugi 31 : 9-17, 1982.
 
6) Pinnas JL, Tan EM, Teplitz RL, et al : Autosensitization to DNA : evidence for an immunologic basis. J Invest Dermatol 72 : 157-160, 1979.
PubMed
7) Sugai S, Yasuda Y, Shimizu S, et al : DNA autosensitivity in two Japanese sisters. Arthritis Rheum 33 : 287-292, 1990.
PubMed
8) Little AS, Bell HE : Painful subcutaneous hemorrhages of the extremities with unusual reaction to injected deoxyribonucleic acid. Ann Intern Med 60 : 886-891, 1964.
PubMed
9) Gardner FH, Diamond LK : Autoerythrocyte sensitization ; a form of purpura producing painful bruising following autosensitization to red blood cells in certain women. Blood 10 : 675-690, 1955.
PubMed
10) Coppola A, Tufano A, Di Capua M, et al : Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 37 : 929-945, 2011.
PubMed
11) Anderson PC, McCaffree MK : Pseudo DNA autosensitivity. A factitial disease. JAMA 196 : 104-105, 1966.
PubMed
12) Parker FS, Irvin JL : The interaction of chloroquine with nucleic acids and nucleoproteins. J Biol Chem 199 : 897-909, 1952.
PubMed
P.133 掲載の参考文献
1) Gardner FH, Diamond LK : Autoerythrocyte sensitization ; a form of purpura producing painful bruising following autosensitization to red blood cells in certain women. Blood 10 : 675-690, 1955.
PubMed
2) Sridharan M, Ali U, Hook CC, et al : The Mayo Clinic Experience With Psychogenic Purpura (Gardner-Diamond Syndrome). Am J Med Sci 357 : 411-420, 2019.
 
3) Ratnoff OD : The psychogenic purpuras : a review of autoerythrocyte sensitization, autosensitization to DNA, "hysterical" and factitial bleeding, and the religious stigmata. Semin Hematol 17 : 192-213, 1980.
PubMed
4) Silny W, Marciniak A, Czarnecka-Operacz M, et al : Gardner-Diamond syndrome. Int J Dermatol 49 : 1178-1181, 2010.
PubMed
5) Durmazlar SP, Atacan D, Cemil B, et al : Is Gardner-Diamond syndrome associated with hormonal influences along with psychosocial problems? A delayed diagnosis. Eur J Dermatol 19 : 259-260, 2009.
 
6) Ivanov OL, Lvov AN, Michenko AV, et al : Autoerythrocyte sensitization syndrome (Gardner Diamond syndrome) : review of the literature. J Eur Acad Dermatol Venereol 23 : 499-504, 2009.
PubMed
7) Al Hawsawi K, Pope E : Pediatric psychocutaneous disorders : a review of primary psychiatric disorders with dermatologic manifestations. Am J Clin Dermatol 12 : 247-257, 2011.
PubMed
8) Uthman IW, Moukarbel GV, Salman SM, et al : Autoerythrocyte sensitization (Gardner-Diamond) syndrome. Eur J Haematol 65 : 144-147, 2000.
PubMed
9) Levin MB, Pinkus H : Autosensitivity to desoxyribonucleic acid (DNA). Report of a case with inflammatory skin lesions controlled by chloroquine. N Engl J Med 264 : 533-537, 1961.
PubMed
10) Coppola A, Tufano A, Di Capua M, et al : Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 37 : 929-945, 2011.
PubMed
11) Gomi H, Miura T : Autoerythrocyte sensitization syndrome with thrombocytosis. Dermatology 188 : 160-162, 1994.
PubMed
12) Settle EC Jr : Autoerythrocyte sensitization successfully treated with antidepressants. JAMA 250 : 1749-1750, 1983.
PubMed
13) Harada K, Hagiwara T : Gardner-Diamond syndrome complicated with chronic urticaria successfully treated with antihistamine. J Dermatol 49 : e75-e76, 2022.
PubMed
P.136 掲載の参考文献
1) Leslie T : Purpura. In : Rook's Textbook of Dermatology, 9th edition (ed by Barker J, Bleiker TO, Chalmers R, et al), Wiley-Blackwell, Oxford, 2016.
 
2) 塚本克彦 : 血管性紫斑. In : 玉置俊彦, ed. 最新皮膚科学大系 (玉置邦彦総集編), 第4巻 紅班・滲出性紅班紫斑脈管系の疾患, 中山書店, 2003.
 
3) Capewell S, Reynolds S, Shuttleworth D, et al : Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ 300 : 1548-1551, 1990.
PubMed
4) Shibli-Rahhal A, Van Beek M, Schlechte JA : Cushing's syndrome. Clin Dermatol 24 : 260-265, 2006.
PubMed
5) Ropke MA, Alonso C, Jung S, et al : Effects of glucocorticoids on stratum corneum lipids and function in human skin-A detailed lipidomic analysis. J Dermatol Sci 88 : 330-338, 2017.
PubMed
6) Niculet E, Bobeica C, Tatu AL : Glucocorticoid-Induced Skin Atrophy : The Old and the New. Clin Cosmet Investig Dermatol 13 : 1041-1050, 2020.
PubMed
7) Schoepe S, Schacke H, May E, et al : Glucocorticoid therapy-induced skin atrophy. Exp Dermatol 15 : 406-420, 2006.
PubMed
8) Schacke H, Docke WD, Asadullah K : Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96 : 23-43, 2002.
PubMed
9) Chen SJ, Yuan W, Lo S, et al : Interaction of smad3 with a proximal smad-binding element of the human alpha2 (I) procollagen gene promoter required for transcriptional activation by TGF-beta. J Cell Physiol 183 : 381-392, 2000.
PubMed
10) Song CZ, Tian X, Gelehrter TD : Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci U S A 96 : 11776-11781, 1999.
PubMed
11) Oishi Y, Fu ZW, Ohnuki Y, et al : Molecular basis of the alteration in skin collagen metabolism in response to in vivo dexamethasone treatment : effects on the synthesis of collagen type I and III, collagenase, and tissue inhibitors of metalloproteinases. Br J Dermatol 147 : 859-868, 2002.
PubMed
12) Alan I, Aian B : 6. Side effects of glucocorticoids. In : Pharmacokinetics and Adverse Effects of Drugs-Mechanisms and Risk Factors. (ed by Malangu N), IntechOpen, London, 2018.
 
P.141 掲載の参考文献
1) Scurvy and its prevention and control in major emergencies. World Health Organization, United Nations High Commissioner for Refugees, 1999.
 
2) 厚生労働省「日本人の食事摂取基準 (2020年版) 」. ビタミン (水溶性ビタミン). [https://www.mhlw.go.jp/content/10904750/000586563.pdf]
 
3) Magiorkinis E, Beloukas A, Diamantis A : Scurvy : past, present and future. Eur J Intern Med 22 : 147-152, 2011.
PubMed
4) Dresen E, Lee ZY, Hill A, et al : History of scurvy and use of vitamin C in critical illness : A narrative review. Nutr Clin Pract 38 : 46-54, 2023.
PubMed
5) Rajakumar K : Infantile scurvy : a historical perspective. Pediatrics 108 : E76, 2001.
PubMed
6) Velandia B, Centor RM, McConnell V, et al : Scurvy is still present in developed countries. J Gen Intern Med 23 : 1281-1284, 2008.
PubMed
7) 間瀬勘史 : 壊血病, Moller-Barlow病. 別冊日本臨牀 血液症候群 II, p405-407, 1998.
 
8) Ghedira Besbes L, Haddad S, Ben Meriem C, et al : Infantile scurvy : two case reports. Int J Pediatr 2010 : 717518, 2010.
PubMed
9) 平松成美, 桑野史穂美, 徳山清信, ほか : 今月の症例 下腿出血を繰り返し最終的に壊血病と診断した1例. 日本内科学会雑誌 110 : 2256-2261, 2021.
 
P.146 掲載の参考文献
1) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
2) Brogan P, Eleftheriou D, Dillon M : Small vessel vasculitis. Pediatr Nephrol 25 : 1025-1035, 2010.
PubMed
3) Jelusic M, Sestan M : IgA vasculitis or Henoch-Schonlein purpura : genetics and beyond. Pediatr Nephrol 36 : 2149-2153, 2021.
 
4) Ozen S, Marks SD, Brogan P, et al : European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis-the SHARE initiative. Rheumatology (Oxford) 58 : 1607-1616, 2019.
PubMed
5) Saulsbury FT : Clinical update : Henoch-Schonlein purpura. Lancet 369 : 976-978, 2007.
PubMed
6) Oni L, Sampath S : Childhood IgA Vasculitis (Henoch Schonlein Purpura) -Advances and Knowledge Gaps. Front Pediatr 7 : 257, 2019.
PubMed
7) Sestan M, Jelusic M : Diagnostic and Management Strategies of IgA Vasculitis Nephritis/Henoch-Schonlein Purpura Nephritis in Pediatric Patients : Current Perspectives. Pediatric Health Med Ther 14 : 89-98, 2023.
PubMed
8) 小児IgA血管炎診療ガイドライン 2023 (日本小児腎臓病学会編), 診断と治療社, 2023.
 
9) Reamy BV, Williams PM, Lindsay TJ : Henoch-Schonlein purpura. Am Fam Physician 80 : 697-704, 2009.
PubMed
10) Hastings MC, Rizk DV, Kiryluk K, et al : IgA vasculitis with nephritis : update of pathogenesis with clinical implications. Pediatr Nephrol 37 : 719-733, 2022.
PubMed
11) Ozen S, Pistorio A, Iusan SM, et al : EULAR/PRINTO/PRES criteria for Henoch-Schonlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis : Ankara 2008. Part II : Final classification criteria. Ann Rheum Dis 69 : 798-806, 2010.
PubMed
12) Fujiwara K, Shimizu J, Tsukahara H, et al : Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulin-A vasculitis : a report of Japanese sibling cases and review of the literature. Rheumatol Int 39 : 1811-1819, 2019.
PubMed
13) Leducq S, Maruani A, Bodemer C, et al : Accurate diagnosis of acute hemorrhagic edema of infancy : a French multicenter observational study. Eur J Pediatr, 2023. (DOI : 10.1007/s00431-023-05098-7)
 
14) Marzano AV, Maronese CA, Genovese G, et al : Urticarial vasculitis : Clinical and laboratory findings with a particular emphasis on differential diagnosis. J Allergy Clin Immunol 149 : 1137-1149, 2022.
PubMed
15) Ronkainen J, Nuutinen M, Koskimies O : The adult kidney 24 years after childhood Henoch-Schonlein purpura : a retrospective cohort study. Lancet 360 : 666-670, 2002
PubMed
P.151 掲載の参考文献
1) 山村昌弘 : 薬剤起因性好中球細胞質抗体関連血管炎の現状. リウマチ科 69 : 79-83, 2023.
 
2) Jennette JC, Falk RJ, Bacon PA, et al : 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65 : 1-11, 2013.
 
3) 古川福実, 池田高治, 石黒直子, ほか : 血管炎・血管障害診察ガイドライン 2016年改訂版. 日本皮膚科学会誌 127 : 299-415, 2017.
 
4) Choi HK, Merkel PA, Walker AM, et al : Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis : prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 43 : 405-413, 2000.
PubMed
5) Deshayes S, Dolladille C, Dumont A, et al : A Worldwide Pharmacoepidemiologic Update on Drug-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in the Era of Targeted Therapies. Arthritis Rheumatol 74 : 134-139, 2022.
 
6) Zhao MH, Chen M, Gao Y, et al : Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int 69 : 1477-1481, 2006.
PubMed
7) Jiang X, Khursigara G, Rubin RL : Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 266 : 810-813, 1994.
PubMed
8) Lee E, Hirouchi M, Hosokawa M, et al : Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 37 : 2151-2153, 1988.
PubMed
9) Nakazawa D, Tomaru U, Suzuki A, et al : Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps : implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 64 : 3779-3787, 2012.
 
10) Gao Y, Ye H, Yu F, et al : Anti-myeloperoxidase IgG subclass distribution and avidity in sera from patients with propylthiouracil-induced antineutrophil cytoplasmic antibodies associated vasculitis. Clin Imuunol 117 : 87-93, 2005.
PubMed
P.155 掲載の参考文献
1) 塚本克彦 : 血管性紫斑単純性紫斑. 最新皮膚科学大系 (玉置邦彦総編集), 第4巻, p99-101, 中山書店, 2003.
 
2) 大塚藤男, 藤本学 (編) : デビス紫斑. 皮膚科学 第11版, p243, 金芳堂, 2022.
 
3) Davis E, Manc MD : Hereditary familial purpura simplex. Review of 27 families. Lancet 237 : 145-146, 1941.
 
4) Storan ER, McEvoy MT, Wetter DA, et al : Experience of a year of adult hospital dermatology consultations. Int J Dermatol 54 : 1150-1156, 2015.
PubMed
5) Davis E, Manc MD : Purpura of the skin. A review of 500 cases. Lancet 242 : 160-161, 1943.
 
6) 安齋眞一 : 単純性紫斑. 皮膚病理診断リファレンス, p55-56, 医学書院, 2020.
 
7) 川名誠司, 陳科榮 : 単純性紫斑. 皮膚血管炎 第2版, p419-421, 医学書院, 2022.
 
P.158 掲載の参考文献
1) 塚本克彦 : 血管性紫斑老人性紫斑. 最新皮膚科学大系 (玉置邦彦総編集), 第4巻, p90-91, 中山書店, 2003.
 
2) Beauregard S, Gilchrest BA : A survey of skin problems and skin care regimens in the elderly. Arch Dermatol 123 : 1638-1643, 1987.
PubMed
3) Wong HY : Hypothesis : senile purpura is a prognostic feature in elderly patients. Age Ageing 17 : 422-424, 1988.
PubMed
4) Cho SI, Kim JW, Yeo G, et al : Senile Purpura : Clinical Features and Related Factors. Ann Dermatol 31 : 472-475, 2019.
PubMed
5) Shuster S, Scarborough H : Senile purpura. Q J Med 30 : 33-40, 1961.
 
6) 川田暁, 佐藤貴浩, 山本俊幸 : 老人性紫斑. 見てわかる皮膚疾患 診察室におきたいアトラス, p109, 中外医学社, 2019.
 
7) 立花隆夫 : 老人性紫斑. 皮膚疾患ペディア (片山一朗監, 浅井俊弥, 岩月啓氏, 横関博雄編), p166, 日本医師会, 2016.
 
8) 加藤晴久 : 老人性紫斑発症機序における真皮内微小血管および結合織の光顕的・電顕的研究-ステロイド紫斑との比較・検討-. 皮膚 36 : 597-612, 1994.
 
9) 川名誠司, 陳科榮 : 老人性紫斑およびステロイド紫斑. 皮膚血管炎 第2版, p419-420, 医学書院, 2022.
 

VII 凝固・線溶異常による出血傾向

P.167 掲載の参考文献
1) Iorio A, Stonebraker JS, Chambost H, et al : Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males : A Meta-analytic Approach Using National Registries. Ann Intern Med 171 : 540-546, 2019.
 
2) Soucie JM, Evatt B, Jackson D : Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 59 : 288-294, 1998.
PubMed
3) 血液凝固異常症全国調査運営委員会 : 厚生労働省委託事業 血液凝固異常症全国調査 令和4年度報告書, p3, 公益財団法人エイズ予防財団, 2023.
 
4) Kemball-Cook G, Tuddenham EG, Wacey AI : The factor VIII Structure and Mutation Resource Site : HAMSTeRS version 4. Nucleic Acids Res 26 : 216-219, 1998.
PubMed
5) 小倉妙美, 堀越泰雄 : II. 診断 1. 臨床症状. みんなに役立つ血友病の基礎と臨床, 改訂版 (白幡聡編), p104-115, 医薬ジャーナル社, 2012.
 
6) Zanon E, Iorio A, Rocino A, et al : Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. Haemophilia 18 : 39-45, 2012.
PubMed
7) Melchiorre D, Manetti M, Matucci-Cerinic M : Pathophysiology of Hemophilic Arthropathy. J Clin Med 6 : 63, 2017.
 
8) Rodriguez-Merchan EC : Hemophilic Pseudotumors : Diagnosis and Management. Arch Bone Jt Surg 8 : 121-130, 2020.
PubMed
9) Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al : Guidelines for the treatment of hemophilia. Haemophilia 19 : e1-e47, 2013.
 
10) van Galen K, d'Oiron R, James P, et al : A new hemophilia carrier nomenclature to define hemophilia in women and girls : Communication from the SSC of the ISTH. J Thromb Haemost 19 : 1883-1887, 2021.
 
11) 藤井輝久, 天野景裕, 渥美達也, ほか : インヒビターのない血友病患者に対する止血治療ガイドライン, 2013年改訂版. 日本血栓止血誌 24 : 619-639, 2013.
 
12) 酒井道生, 瀧正志, 家子正裕, ほか : インヒビター保有先天性血友病患者に対する止血治療ガイドライン, 2013年改訂版. 日本血栓止血誌 24 : 640-658, 2013.
 
13) Nilsson IM, Berntorp E, Lofqvist T, et al : Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 232 : 25-32, 1992.
 
14) Kitazawa T, Igawa T, Sampei Z, et al : A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med 18 : 1570-1574, 2012.
 
15) Srivastava A, Santagostino E, Dougall A, et al : WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 26 (Suppl 6) : 1-158, 2020.
 
P.172 掲載の参考文献
1) Ponder KP : Merry christmas for patients with hemophilia B. N Engl J Med 365 : 2424-2425, 2011.
PubMed
2) 村田萌, 小嶋哲人 : 3. 血友病の病態 4) 血友病Bの分子生物学. みんなに役立つ血友病の基礎と臨床, 改訂版 (白幡聡編), p51-58, 医薬ジャーナル社, 2012.
 
3) Sidonio RF Jr, Malec L : Hemophilia B (Factor IX Deficiency). Hematol Oncol Clin North Am 35 : 1143-1155, 2021.
PubMed
4) Iorio A, Stonebraker JS, Chambost H, et al : Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males : A Meta-analytic Approach Using National Registries. Ann Intern Med 171 : 540-546, 2019.
 
5) 血液凝固異常症全国調査運営委員会 : 厚生労働省委託事業 血液凝固異常症全国調査 令和4年度報告書, p3, 公益財団法人エイズ予防財団, 2023.
 
6) Rogaev EI, Grigorenko AP, Faskhutdinova G, et al : Genotype analysis identifies the cause of the "royal disease". Science 326 : 817, 2009.
PubMed
7) Belvini D, Salviato R, Radossi P, et al : Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 90 : 635-642, 2005.
PubMed
8) Mannucci PM, Franchini M : Is haemophilia B less severe than haemophilia A? Haemophilia 19 : 499-502, 2013.
 
9) Chalmers EA, Alamelu J, Collins PW, et al : Intracranial haemorrhage in children with inherited bleeding disorders in the UK 2003-2015 : A national cohort study. Haemophilia 24 : 641-647, 2018.
PubMed
10) 藤井輝久, 天野景裕, 渥美達也, ほか : インヒビターのない血友病患者に対する止血治療ガイドライン, 2013年改訂版. 日本血栓止血誌 24 : 619-639, 2013.
 
11) 酒井道生, 瀧正志, 家子正裕, ほか : インヒビター保有先天性血友病患者に対する止血治療ガイドライン, 2013年改訂版. 日本血栓止血誌 24 : 640-658, 2013.
 
12) Mahdi AJ, Obaji SG, Collins PW : Role of enhanced half-life factor VIII and IX in the treatment of haemophilia. Br J Haematol 169 : 768-776, 2015.
PubMed
13) Cooley B, Funkhauser W, Monroe D, et al : Prophylactic efficacy of BeneFIX vs Alprolix in hemophilia B mice. Blood 128 : 286-292, 2016.
 
14) Gui T, Reheman A, Ni H, et al : Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV. J Thromb Haemost 7 : 1843-1851, 2009.
 
15) Burke T, Shaikh A, Ali TM, et al : Association of factor expression levels with annual bleeding rate in people with haemophilia B. Haemophilia 29 : 115-122, 2023.
 
P.175 掲載の参考文献
1) Nishino M, Girma JP, Rothschild C, et al : New variant of von Willebrand disease with defective binding to factor VIII. Blood 74 : 1591-1599, 1989.
PubMed
2) Gaucher C, Jorieux S, Mercier B, et al : The "Normandy" variant of von Willebrand disease : characterization of a point mutation in the von Willebrand factor gene. Blood 77 : 1937-1941, 1991.
PubMed
3) Tuley EA, Gaucher C, Jorieux S, et al : Expression of von Willebrand factor "Normandy" : an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci U S A 88 : 6377-6381, 1991.
PubMed
4) Sadler JE : A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 71 : 520-525, 1994.
PubMed
5) Foster PA, Fulcher CA, Marti T, et al : A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J Biol Chem 262 : 8443-8446, 1987.
 
6) Mazurier C, Meyer D : Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease-results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 76 : 270-274, 1996.
 
7) 嶋緑倫 : 第VIII因子結合能異常症 ; 凝固線溶異常による出血傾向. 先天性凝固線溶異常症. 血友病および類縁疾患. 別冊日本臨牀 領域別症候群シリーズ No.21 血液症候群 II, p430-433, 日本臨牀社, 1998.
 
P.178 掲載の参考文献
1) Blat Y, Seiffert D : A renaissance for the contact system in blood coagulation? Thromb Haemost 99 : 457-460, 2008.
 
2) Waldmann R, Abraham JP, Rebuck JW, et al : Fitzgerald factor : a hitherto unrecognised coagulation factor. Lancet 1 : 949-951, 1975.
PubMed
3) Colman RW, Bagdasarian A, Talamo RC, et al : Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 56 : 1650-1662, 1975.
PubMed
4) Wuepper KD, Miller DR, Lacombe MJ : Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 56 : 1663-1672, 1975.
PubMed
5) Hayashi H, Koya H, Kuroda M, et al : The first cases of Fitzgerald factor deficiency in the Orient : three cases in one family. Acta Haematol 63 : 107-113, 1980.
PubMed
6) Hayashi H, Ishimaru F, Fujita T, et al : Molecular genetic survey of five Japanese families with high-molecular-weight kininogen deficiency. Blood 75 : 1296-1304, 1990.
PubMed
7) Adenaeuer A, Barco S, Trinchero A, et al : Severe high-molecular-weight kininogen deficiency : clinical characteristics, deficiency-causing KNG1 variants, and estimated prevalence. J Thromb Haemost 21 : 237-254, 2023.
PubMed
8) Krijanovski Y, Proulle V, Mahdi F, et al : Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient : insights into structural requirements for kininogen expression. Blood 101 : 4430-4436, 2003.
PubMed
9) ShigekiyoT, Miyagi J, Shirakami A, et al : Isolated high-molecular-weight kininogen deficiency : a novel frameshift mutation in exon 10. Blood 109 : 5063-5063, 2007.
 
10) Cheung PP, Kunapuli SP, Scott CF, et al : Genetic basis of total kininogen deficiency in Williams' trait. J Biol Chem 268 : 23361-23365, 1993.
PubMed
11) Davidson SJ, Burman JF, Rutherford LC, et al : High molecular weight kininogen deficiency : a patient who underwent cardiac surgery. Thromb Haemost 85 : 195-197, 2001.
PubMed
P.181 掲載の参考文献
1) Lowenberg EC, Meijers JC, Monia BP, et al : Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost 8 : 2349-2357, 2010.
PubMed
2) Mann KG, Kalafatis M : Factor V : a combination of Dr Jekyll and Mr Hyde. Blood 101 : 20-30, 2003.
 
3) Oeri J, Matter M, Isenschmid H, et al : Congenital factor V deficiency (parahemophilia) with true hemophilia in two brothers. Bibl Paediatr 58 : 575-588, 1954.
PubMed
4) World Federation of Hemophilia Report on the Annual Global Survey 2021. [https://www1.wfh.org/publications/files/pdf-2324.pdf]
 
5) Spreafico M, Peyvandi F : Combined factor V and factor VIII deficiency. Semin Thromb Hemost 35 : 390-399, 2009.
PubMed
6) Nichols WC, Seligsohn U, Zivelin A, et al : Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell 93 : 61-70, 1998.
PubMed
7) Zhang B, Cunningham MA, Nichols WC, et al : Bleeding due to disruption of a cargo-specific ER-to-Golgi transport complex. Nat Genet 34 : 220-225, 2003.
PubMed
8) Zhang B, Kaufman RJ, Ginsburg D : LMAN1 and MCFD2 form a cargo receptor complex and interact with coagulation factor VIII in the early secretory pathway. J Biol Chem 280 : 25881-25886, 2005.
 
9) Peyvandi F, Tuddenham EG, Akhtari AM, et al : Bleeding symptoms in 27 Iranian patients with the combined deficiency of factor V and factor VIII. Br J Haematol 100 : 773-776, 1998.
PubMed
10) Mansouritorgabeh H, Rezaieyazdi Z, Pourfathollah AA, et al : Haemorrhagic symptoms in patients with combined factors V and VIII deficiency in north-eastern Iran. Haemophilia 10 : 271-275, 2004.
PubMed
11) Zhang B, Spreafico M, Zheng C, et al : Genotype-phenotype correlation in combined deficiency of factor V and factor VIII. Blood 111 : 5592-5600, 2008.
PubMed
12) Bolton-Maggs PHB, Perry DJ, Chalmers EA, et al : The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 10 : 593-628, 2004.
PubMed
13) Shao Y, Wu W, Xu G, et al : Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII. Blood 134 : 1745-1754, 2019.
PubMed
P.185 掲載の参考文献
1) Mann KG, Kalafatis M : Factor V : a combination of Dr Jekyll and Mr Hyde. Blood 101 : 20-30, 2003.
 
2) Owren PA : Parahaemophilia ; haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet 1 : 446-448, 1947.
PubMed
3) World Federation of Hemophilia Report on the Annual Global Survey 2021. [https://www1.wfh.org/publications/files/pdf-2324.pdf]
 
4) Lak M, Sharifian R, Peyvandi F, et al : Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 103 : 1067-1069, 1998.
PubMed
5) Asselta R, Peyvandi F : Factor V deficiency. Semin Thromb Haemost 35 : 382-389, 2009.
 
6) Guasch JF, Cannegieter S, Reitsma PH, et al : Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Haematol 101 : 32-39, 1998.
PubMed
7) Zivelin A, Seligsohn U : Summary of mutations causing rare bleeding disorders, Factor V. In : Supplement to Chapter 125 of Williams Hematology 8th Edition, 2010. [https://cdn.ymaws.com/www.isth.org/resource/resmgr/publications/fv_mutations-2011.pdf]
 
8) Castoldi E, Lunghi B, Mingozzi F, et al : A missense mutation (Y1702C) in the coagulation factor V gene is a frequent cause of factor V deficiency in the Italian population. Haematologica 86 : 629-633, 2001.
PubMed
9) Acharya SS, Coughlin A, Dimichele DM, et al : Rare bleeding disorder registry : deficiencies of factors II, V, VII, X, XIII, fibrinogen and dysfibrinogenemias. J Thromb Haemost 2 : 248-256, 2004.
PubMed
10) 小児慢性特定疾病情報センター : 38. 第V因子欠乏症. [https://www.shouman.jp/disease/instructions/09_21_038/]
 
11) Bolton-Maggs PH, Perry DJ, Chalmers EA, et al : The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 10 : 593-628, 2004.
PubMed
12) Drzymalski DM, Elsayes AH, Ward KR, et al : Platelet transfusion as treatment for factor V deficiency in the parturient : a case report. Transfusion 59 : 2234-2237, 2019.
PubMed
13) Gonzalez-Boullosa R, Ocampo-Martinez R, Alarcon-Martin MJ, et al : The use of activated recombinant coagulation factor VII during haemarthroses and synovectomy in a patient with congenital severe factor V deficiency. Haemophilia 11 : 167-170, 2005.
 
14) Seki T, Tsukagoshi M, Harimoto N, et al : Laparoscopic hepatectomy for hepatocellular carcinoma in a patient with congenital factor V deficiency : a case report. Surg Case Rep 8 : 202, 2022.
 
P.189 掲載の参考文献
1) Telfer TP, Denson KW, Wright DR, et al : A new coagulation defect. Br J Haematol 2 : 308-316, 1956.
PubMed
2) Hougie C, Barrow EM, Graham JB : Stuart clotting defect. I. Segregation of an hereditary hemorrhagic state from the heterogeneous group heretofore called stable factor (SPCA, proconvertin, factor VII) deficiency. J Clin Invest 36 : 485-496, 1957.
PubMed
3) Denson KW, Lurie A, De Cataldo F, et al : The factor-X defect : Recoginition of abnormal forms of Factor X. Br J Haematol 18 : 317-327, 1970.
 
4) Zama T, Murata M, Watanabe R, et al : A family with hereditary factor X deficiency with a point mutation Gla32 to Gln in the Gla domain (factor X Tokyo). Br J Haematol 106 : 809-811, 1999.
 
5) Leytus SP, Foster DC, Kurachi K, et al : Gene for human factor X : a blood coagulation factor whose gene organization is essentially identical with that of factor IX and protein C. Biochemistry 25 : 5098-5102, 1986.
PubMed
6) Royle NJ, Fung MR, MacGillivray RT, et al : The gene for clotting factor 10 is mapped to 13q32→qter. Cytogenet Cell Genet 41 : 185-188, 1986.
 
7) Henkens CM, Bom VJ, Van der Schaaf W, et al : Plasma levels of protein S, protein C, and factor X : effects of sex, hormonal state and age. Thromb Haemost 74 : 1271-1275, 1995.
PubMed
8) Girolami A, Molaro G, Lazzarin M, et al : A new congenital hemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli) : study of a large kindred. Br J Haematol 19 : 179-192, 1970.
 
9) Watzke HH, Wallmark A, Hamaguchi N, et al : Factor XSanto Domingo. Evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest 88 : 1685-1689, 1991.
PubMed
10) Reddy SV, Zhou ZQ, Rao KJ, et al : Molecular characterization of human factor XSan Antonio. Blood 74 : 1486-1490, 1989.
PubMed
11) Harris VA, Lin W, Perkins SJ : Analysis of 180 Genetic Variants in a New Interactive FX Variant Database Reveals Novel Insights into FX Deficiency. TH Open 5 : e557-e569, 2021.
 
12) Greipp PR, Kyle RA, Bowie EJ : Factor-X deficiency in amyloidosis : a critical review. Am J Hematol 11 : 443-450, 1981.
PubMed
13) Palla R, Peyvandi F, Shapiro AD : Rare bleeding disorders : diagnosis and treatment. Blood 125 : 2052-2061, 2015.
PubMed
14) Liang Q, Chen Q, Ding Q, et al : Six novel missense mutations causing factor X deficiency and application of thrombin generation test. Thromb Res 131 : 554-559, 2013.
PubMed
15) Chikasawa Y, Shinozawa K, Amano K, et al : Factor X M402T : a homozygous missense mutation identified as the cause of cross-reacting material-reduced deficiency. Int J Hematol 100 : 345-352, 2014.
PubMed
P.194 掲載の参考文献
1) Fujikawa K, Chung DW, Hendrickson LE, et al : Amino acid sequence of human factor XI, a blood coagulation factor with four tandem repeats that are highly homologous with plasma prekallikrein. Biochemistry 25 : 2417-2424, 1986.
PubMed
2) Asakai R, Davie EW, Chung DW : Organization of the gene for human factor XI. Biochemistry 26 : 7221-7228, 1987.
PubMed
3) McMullen BA, Fujikawa K, Davie EW : Location of the disulfide bonds in human coagulation factor XI : the presence of tandem apple domains. Biochemistry 30 : 2056-2060, 1991.
PubMed
4) Mohammed BM, Matafonov A, Ivanov I, et al : An update on factor XI structure and function. Thromb Res 161 : 94-105, 2018.
PubMed
5) He R, Chen D, He S : Factor XI : hemostasis, thrombosis, and antithrombosis. Thromb Res 129 : 541-550, 2012.
PubMed
6) Kato A, Asakai R, Davie EW, et al : Factor XI gene (F11) is located on the distal end of the long arm of human chromosome 4. Cytogenet Cell Genet 52 : 77-78, 1989.
 
7) Cheng Q, Kantz J, Poffenberger G, et al : Factor XI protein in human pancreas and kidney. Thromb Haemost 100 : 158-160, 2008.
PubMed
8) Naito K, Fujikawa K : Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 266 : 7353-7358, 1991.
PubMed
9) Kravtsov DV, Matafonov A, Tucker EI, et al : Factor XI contributes to thrombin generation in the absence of factor XII. Blood 114 : 452-458, 2009.
PubMed
10) von dem Borne PA, Meijers JC, Bouma BN : Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 86 : 3035-3042, 1995.
PubMed
11) Von dem Borne PA, Bajzar L, Meijers JC, et al : Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 99 : 2323-2327, 1997.
 
12) Preis M, Hirsch J, Kotler A, et al : Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. Blood 129 : 1210-1215, 2017.
PubMed
13) Asakai R, Chung DW, Davie EW, et al : Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 325 : 153-158, 1991.
 
14) Kravtsov DV, Monahan PE, Gailani D : A classification system for cross-reactive materialnegative factor XI deficiency. Blood 105 : 4671-4673, 2005.
PubMed
15) Harris VA, Lin W, Perkins SJ : Analysis of 272 Genetic Variants in the Upgraded Interactive FXI Web Database Reveals New Insights into FXI Deficiency. TH Open 5 : e543-e556, 2021.
PubMed
16) Salomon O, Steinberg DM, Seligshon U : Variable bleeding manifestations characterize different types of surgery in patients with severe factor XI deficiency enabling parsimonious use of replacement therapy. Haemophilia 12 : 490-493, 2006.
PubMed
17) Duga S, Salomon O : Factor XI Deficiency. Semin Thromb Hemost 35 : 416-425, 2009.
PubMed
18) Nossel HL, Niemetz J, Sawitsky A, et al : Blood PTA (factor XI) levels following plasma infusion. Pro Soc Exp Biol Med 115 : 896-897, 1964.
 
19) Livnat T, Tamarin I, Mor Y, et al : Recombinant activated factor VII and tranexamic acid are haemostatically effective during major surgery in factor XI-deficient patients with inhibitor antibodies. Thromb Haemost 102 : 487-492, 2009.
PubMed
P.200 掲載の参考文献
1) Hantgan RR, Simpson-Haidaris PJ, Francis CW, et al : Fibrinogen structure and physiology. In : Hemostasis and Thrombosis, 4th edition (ed by Colman RW, Hirsh J, Marder VJ, et al.), p203-232, Lippincott Williams & Wilkins, Philadelphia, 2001.
 
2) 諏合輝子 : フィブリノゲンの基礎と臨床. 図説血栓・止血・血管学 (一瀬白帝編), p280-285, 中外医学社, 2005.
 
3) Tuddenham ED, Cooper DN : Fibrinogen. In : The Molecular Genetics of Haemostasis and its Inherited Disorders, p248-270, Oxford Medical Publications, New York, 1994.
 
4) 小林隆夫, 寺尾俊彦, 高松純樹 : 先天性無フィブリノゲン血症-妊娠・分娩管理を中心に-日本血栓止血学会誌 12 : 57-65, 2001.
 
5) Asselta R, Duga S, Tenchini ML : The molecular basis of quantitative fibrinogen disorders. J Thromb Haemost 4 : 2115-2129, 2006.
PubMed
6) Laffan M : Fibrinogen. In : Textbook of Hemophilia, 2nd Edition (ed by Lee CA, Berntorp EE, Hoots WK), p369-368, Blackwell Publishing, West Sussex, 2010.
 
7) Soria J, Soria C, Samama M, et al : Fibrinogen Troyes-fibrinogen Metz. Two new cases of congenital dysfibrinogenemia. Thromb Diath Haemorrh 27 : 619-633, 1972.
PubMed
8) Wada Y, Niwa K, Maekawa H, et al : A new type of congenital dysfibrinogen, fibrinogen Bremen, with an A alpha Gly-17 to Val substitution associated with hemorrhagic diathesis and delayed wound healing. Thromb Haemost 70 : 397-403, 1993.
PubMed
9) 松田道生, 諏合輝子, 中三川千鶴子, ほか : 遺伝性異常フィブリノゲン血症. 日本血栓止血学会誌 12 : 47-56, 2001.
 
10) Kobayashi T, Kanayama N, Tokunaga N, et al : Prenatal and peripartum management of congenital afibrinogenaemia. Br J Haematol 109 : 364-366, 2000.
PubMed
P.202 掲載の参考文献
1) Quick AJ : Congenital hypoprothrombinaemia and pseudo-hypoprothrombinaemia. Lancet 2 : 379-382, 1947.
PubMed
2) Shapiro SS, Martinez J, Holburn RR : Congenital dysprothrombinemia : an inherited structural disorder of human prothrombin. J Clin Invest 48 : 2251-2259, 1969.
PubMed
3) Fujimura Y, Nakane N, Sugimoto M, et al : Congenital hypoprothrombinemia : The first reported case in Japan. Acta Paediatr Jpn 26 : 554-560, 1984.
 
4) Inomoto T, Shirakami A, Kawauchi S, et al : Prothrombin Tokushima : characterization of dysfunctional thrombin derived from a variant of human prothrombin. Blood 69 : 565-569, 1987.
PubMed
5) Lancellotti S, De Cristofaro R : Congenital prothrombin deficiency. Semin Thromb Hemost 35 : 367-381, 2009.
PubMed
6) Miyata T, Zheng YZ, Kato A, et al : A point mutation (Arg271→Cys) of a homozygote for dysfunctional prothrombin, prothrombin Obihiro, which has a region of high sequence variability. Br J Haematol 90 : 688-692, 1995.
 
7) Morishita E, Saito M, Kumabashiri I, et al : Prothrombin Himi : a compound heterozygote for two dysfunctional prothrombin molecules (Met-337→Thr and Arg-388→His). Blood 80 : 2275-2280, 1992.
 
8) 森下英理子, 長屋聡美, 丸山慶子, ほか : 先天性複合ヘテロ接合体プロトロンビン欠乏症の一例. 臨床血液 48 : 848, 2007.
 
9) 天野景裕 : 血液凝固異常症全国調査 令和4年度報告書, p10, 公益財団法人エイズ予防財団, 2023.
 
10) Rabiet MJ, Furie BC, Furie B : Molecular defect of prothrombin Barcelona. Substitution of cysteine for arginine at residue 273. J Biol Chem 261 : 15045-15048, 1986.
PubMed
11) Henriksen RA, Mann KG : Identification of the primary structural defect in the dysthrombin thrombin Quick I : substitution of cysteine for arginine-382. Biochemistry 27 : 9160-9165, 1988.
PubMed
12) Henriksen RA, Mann KG : Substitution of valine for glycine-558 in the congenital dysthrombin thrombin Quick II alters primary substrate specificity. Biochemistry 28 : 2078-2082, 1989.
PubMed
13) 野上恵嗣 : 希少出血性疾患 (Rare bleeding disorders) の診断と治療. 日本血栓止血学会誌 33 : 45-52, 2022.
 
P.207 掲載の参考文献
1) Dorgalaleh A, Bahraini M, Shams M, et al : Molecular basis of rare congenital bleeding disorders. Blood Rev 59 : 101029, 2023.
PubMed
2) Sevenet PO, Kaczor DA, Depasse F : Factor VII Deficiency : From Basics to Clinical Laboratory Diagnosis and Patient Management. Clin Appl Thromb Hemost 23 : 703-710, 2017.
PubMed
3) Batsuli G, Kouides P : Rare Coagulation Factor Deficiencies (Factors VII, X, V, and II). Hematol Oncol Clin North Am 35 : 1181-1196, 2021.
PubMed
4) de Moerloose P, Schved JF, Nugent D : Rare coagulation disorders : fibrinogen, factor VII and factor XIII. Haemophilia 22 (Suppl 5) : 61-65, 2016.
 
5) Menegatti M, Palla R : Clinical and laboratory diagnosis of rare coagulation disorders (RCDs). Thromb Res 196 : 603-608, 2020.
PubMed
6) Menegatti M, Peyvandi F : Treatment of rare factor deficiencies other than hemophilia. Blood 133 : 415-424, 2019.
PubMed
7) 一瀬白帝 : 第VII因子欠損症・分子異常症. 別冊日本臨牀 (血液症候群 第2版 II), p533-538, 日本臨牀社, 2013.
 
8) 厚生労働省委託事業, 血液凝固異常症全国調査, 令和3年度報告書, p10, エイズ予防財団, 2022.
 
9) McVey JH, Boswell E, Mumford AD, et al : Factor VII deficiency and the FVII mutation database. Hum Mutat 17 : 3-17, 2001.
PubMed
10) Cooper DN, Millar DS, Wacey A, et al : Inherited factor VII deficiency : molecular genetics and pathophysiology. Thromb Haemost 78 : 151-160, 1997.
PubMed
11) 高宮脩 : 日本人の先天性VII因子欠乏・異常症の遺伝子変異. 日本血栓止血学会誌 19 : 64-76, 2008.
 
12) Peyvandi F, Mannucci PM, Asti D, et al : Clinical manifestations in 28 Italian and Iranian patients with severe factor VII deficiency. Haemophilia 3 : 242-246, 1997.
PubMed
13) Sakakibara K, Okayama Y, Fukushima K, et al : Japanese family with congenital factor VII deficiency. Pediatr Int 57 : 1023-1024, 2015.
PubMed
14) Mulliez SM, Devreese KM : Isolated acquired factor VII deficiency : review of the literature. Acta Clin Belg 71 : 63-70, 2016.
PubMed
15) Abdul-Kadir R, Gomez K : Reproductive health and hemostatic issues in women and girls with congenital factor VII deficiency : A systematic review. J Thromb Haemost 20 : 2758-2772, 2022.
PubMed
P.212 掲載の参考文献
1) Lorand L : Factor XIII : structure, activation, and interactions with fibrinogen and fibrin. Ann NY Acad Sci 936 : 291-311, 2001.
PubMed
2) Ichinose A, Davie EW : Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc Natl Acad Sci U S A 85 : 5829-5833, 1988.
PubMed
3) Bottenus RE, Ichinose A, Davie EW : Nucleotide sequence of the gene for the b subunit of human factor XIII. Biochemistry 29 : 11195-11209, 1990.
 
4) Ichinose A : Physiopathology and regulation of factor XIII. Thromb Haemost 86 : 57-65, 2001.
PubMed
5) Ichinose A : Factor XIII is a key molecule at the intersection of coagulation and fibrinolysis as well as inflammation and infection control. Int J Hematol 95 : 362-370, 2012.
PubMed
6) Javed H, Singh S, Ramaraje Urs SU, et al : Genetic landscape in coagulation factor XIII associated defects-advances in coagulation and beyond. Blood Rev 59 : 101032, 2023.
PubMed
7) Wada H, Souri M, Matsumoto R, et al : Alloantibodies against the B subunit of plasma factor XIII developed in its congenital deficiency. Thromb Haemost 109 : 661-668, 2013.
 
8) Hashiguchi T, Saito M, Morishita E, et al : Two genetic defects in a patient with complete deficiency of the b-subunit for coagulation factor XIII. Blood 82 : 145-150, 1993.
 
9) Izumi T, Hashiguchi T, Castaman G, et al : Type I factor XIII deficiency is caused by a genetic defect of its b subunit : insertion of triplet AAC in exon III leads to premature termination in the second Sushi domain. Blood 87 : 2769-2774, 1996.
PubMed
10) Koseki S, Souri M, Koga S, et al : Truncated mutant B subunit for factor XIII causes its deficiency due to impaired intracellular transportation. Blood 97 : 2667-2672, 2001.
PubMed
11) Ivaskevicius V, Biswas A, Loreth R, et al : Mutations affecting disulphide bonds contribute to a fairly common prevalence of F13B gene defects : results of a genetic study in 14 families with factor XIII B deficiency. Haemophilia 16 : 675-682, 2010.
PubMed
12) Hashiguchi T, Ichinose A : Molecular and cellular basis of deficiency of the b subunit for factor XIII secondary to a Cys430-Phe mutation in the seventh Sushi domain. J Clin Invest 95 : 1002-1008, 1995.
 
13) Souri M, Izumi T, Higashi Y, et al : A founder effect is proposed for factor XIII B subunit deficiency caused by the insertion of triplet AAC in exon III encoding the second Sushi domain. Thromb Haemost 80 : 211-213, 1998.
PubMed
14) Kohler HP, Ichinose A, Seitz R, et al : Diagnosis and classification of factor XIII deficiencies. J Thromb Haemost 9 : 1404-1406, 2011.
PubMed
15) Ichinose A, Osaki T, Souri M : Autoimmune acquired factor XIII deficiency in Japan 2021 update : focused on annual incidence and clinical features. Haemophilia 28 : e121-e124, 2022.
PubMed
16) Souri M, Osaki T, Ichinose A : Anti-factor XIII A subunit (FXIII-A) autoantibodies block A2B2 assembly and steal FXIII-A from native FXIII-A2B2. J Thromb Haemost 13 : 802-814, 2015.
 
P.218 掲載の参考文献
1) Hathaway WE, Belhasen LP, Hathaway HS : Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood 26 : 521-532, 1965.
PubMed
2) Colman RW, Schmaier AH : Contact system : a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90 : 3819-3843, 1997.
PubMed
3) Girolami A, Ferrari S, Cosi E, et al : A structure-function analysis in patients with prekallikrein deficiency. Hematology 23 : 346-350, 2018.
PubMed
4) 金井正光 (監), 奥村伸生, 戸塚実, 本田孝行, ほか (編) : 臨床検査法提要 改訂第35版, p432-434, 金原出版, 2020.
 
5) Shigekiyo T, Fujino O, Kanagawa Y, et al : Prekallikrein (PK) Tokushima : PK deficiency caused by a Gly401→Glu mutation. J Thromb Heamost 1 : 1314-1316, 2003.
 
6) Katsuda I, Maruyama F, Ezaki K, et al : A new type of plasma prekallikrein deficiency associated with homozygosity for Gly104Arg and Asn124Ser in apple domain 2 of the heavychain region. Eur J Haematol 79 : 59-68, 2007.
PubMed
7) 長屋聡美, 森下英理子, 高見昭良, ほか : 高齢になってから診断された先天性プレカリクレイン欠乏症の1症例. 日老医誌 46 : 348-351, 2009.
 
8) 菅崎幹樹, 徳永尚樹, 池亀彰茂, ほか : 術前スクリーニングで偶然発見された先天性プレカリクレイン欠乏症の1症例. 医学検査 70 : 132-137, 2021.
Medical*Online
9) Yu H, Bowden DW, Spray BJ, et al : Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease. Hypertension 31 : 906-911, 1998.
PubMed
10) 桝谷亮太, 田中秀麿, 中西豊文, ほか : APTT試薬の違いが接触因子欠乏症の診断に与える影響-特に血漿プレカリクレイン欠乏症のAPTT測定に対する活性化剤の影響-. 日本検査血液学会雑誌 19 : 33-40, 2018.
 
11) Shigekiyo T, Fujino O : Replacement therapy in a patient with congenital prekallikrein deficiency undergoing surgery. Int J Hematol 56 : 89-93, 1992.
 
P.223 掲載の参考文献
1) van Galen KPM, d'Oiron R, James P, et al : A new hemophilia carrier nomenclature to define hemophilia in women and girls : Communication from the SSC of the ISTH. J Thromb Haemost 19 : 1883-1887, 2021.
 
2) Miller CH, Soucie JM, Byams VR, et al : Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States. Haemophilia 27 : 1037-1044, 2021.
PubMed
3) 天野景裕, 後藤智己, 杉山真一, ほか : 血液凝固異常症全国調査, 令和4年度報告書, p3, 公益財団法人エイズ予防財団, 2023.
 
4) Pavlova A, Brondke H, Musebeck J, et al : Molecular mechanisms underlying hemophilia A phenotype in seven females. J Thromb Haemost 7 : 976-982, 2009.
PubMed
5) David D, Morais S, Ventura C, et al : Female haemophiliac homozygous for the factor VIII intron 22 inversion mutation, with transcriptional inactivation of one of the factor VIII alleles. Haemophilia 9 : 125-130, 2003.
PubMed
6) Vencesla A, Fuentes-Prior P, Baena M, et al : Severe haemophilia A in a female resulting from an inherited gross deletion and a de novo codon deletion in the F8 gene. Haemophilia 14 : 1094-1098, 2008.
 
7) Cai XH, Wang XF, Dai J, et al : Female hemophilia A heterozygous for a de novo frameshift and a novel missense mutation of factor VIII. J Thromb Haemost 4 : 1969-1974, 2006.
 
8) Knobe KE, Sjorin E, Soller MJ, et al : Female haemophilia A caused by skewed X inactivation. Haemophilia 14 : 846-848, 2008.
PubMed
9) Chuansumrit A, Sasanakul W, Goodeve A, et al : Inversion of intron 22 of the factor VIII gene in a girl with severe hemophilia A and Turner's syndrome. Thromb Haemost 82 : 1379, 1999.
 
10) Di Michele DM, Gibb C, Lefkowitz JM, et al : Severe and moderate haemophilia A and B in US females. Haemophilia 20 : e136-e143, 2014.
 
11) Loreth RM, El-Maarri O, Schroder J, et al : Haemophilia A in a female caused by coincidence of a Swyer syndrome and a missense mutation in factor VIII gene. Thromb Haemost 95 : 747-748, 2006.
 
12) Martin-Salces M, Vencesla A, Alvarez-Roman MT, et al : Clinical and genetic findings in five female patients with haemophilia A : Identification of a novel missense mutation, p.Phe2127Ser. Thromb Haemost 104 : 718-723, 2010.
PubMed
13) Schroder W, Poetsch M, Gazda H, et al : A de novo translocation 46, X, t (X ; 15) causing haemophilia B in a girl : a case report. Br J Haematol 100 : 750-757, 1998.
 
14) Favier R, Lavergne JM, Costa JM, et al : Unbalanced X-chromosome inactivation with a novel FVIII gene mutation resulting in severe hemophilia A in a female. Blood 96 : 4373-4375, 2000.
 
15) Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH, et al : Bleeding in carriers of hemophilia. Blood 108 : 52-56, 2006.
PubMed
16) Graham JB, Miller CH, Reisner HM, et al : The phenotypic range of hemophilia A carriers. Am J Hum Genet 28 : 482-488, 1976.
PubMed
17) Valleix S, Vinciguerra C, Lavergne JM, et al : Skewed X-chromosome inactivation in monochorionic diamniotic twin sisters results in severe and mild hemophilia A. Blood 100 : 3034-3036, 2002.
PubMed
18) Sellner LN, Price PJ : Segmental isodisomy and skewed X-inactivation resulting in haemophilia B in a female. Br J Haematol 131 : 410-411, 2005.
 
19) Bicocchi MP, Migeon BR, Pasino M, et al : Familial nonrandom inactivation linked to the X inactivation centre in heterozygotes manifesting haemophilia A. Eur J Hum Genet 13 : 635-640, 2005.
 
P.226 掲載の参考文献
1) Rodriguez-Merchan EC : Musculoskeletal complications of hemophilia. HSS J 6 : 37-42, 2010.
PubMed
2) Baudo F, Collins P, Huth-Kuhne A, et al : Management of bleeding in acquired hemophilia A : results from the European Acquired Haemophilia (EACH2) Registry. Blood 120 : 39-46, 2012.
 
3) Magallon M, Monteagudo J, Altisent C, et al : Hemophilic pseudotumor : multicenter experience over a 25-year period. Am J Hematol 45 : 103-108, 1994.
 
4) Doyle AJ, Back DL, Austin S : Characteristics and management of the haemophilia-associated pseudotumours. Haemophilia 26 : 33-40, 2020.
PubMed
5) Li Z, Weng X : Hemophilic Pseudotumor. N Engl J Med 382 : 2033, 2020.
PubMed
6) Rodriguez-Merchan EC : The haemophilic pseudotumour. Haemophilia 8 : 12-16, 2002.
PubMed
7) Rodriguez-Merchan EC : Haemophilic cysts (pseudotumours). Haemophilia 8 : 393-401, 2002.
PubMed
8) Allen DJ, Goddard NJ, Mann HA, et al : Primary malignancies mistaken for pseudotumours in haemophilic patients. Haemophilia 13 : 383-386, 2007.
PubMed
9) 竹谷英之 : 血友病性関節症と血友病性偽腫瘍. 整形・災害外科 48 : 1247-1254, 2005.
 
10) Lin S, Tong K, Wang G, et al : Clinical characteristics and surgical treatment of haemophilic pseudotumor : A retrospective analysis of thirty-four patients. Haemophilia 26 : 873-881, 2020.
 
11) インヒビターのない血友病患者に対する止血治療ガイドライン 2013年改訂版・2014年補遺版・2015年補遺版 日本血栓止血学会.
 
12) インヒビター保有先天性血友病患者に対する止血治療ガイドライン 2013年改訂版・2014年補遺版・2015年補遺版, 日本血栓止血学会.
 
13) 血友病患者に対する止血治療ガイドライン 2019年補遺版, ヘムライブラ (エミシズマブ) 使用について, 日本血栓止血学会, 2020.
 
14) 厚生労働省委託事業血液凝固異常症全国調査 令和4年度 (2022年度) 報告書. 公益財団法人エイズ予防財団, 2023.
 
15) Kawahara F, Shirayama R, Ito T, et al : Hemophilic pseudotumor of the maxillary sinus in an inhibitor-positive patient with hemophilia A receiving emicizumab : a case report. Int J Hematol 115 : 906-912, 2022.
 
P.232 掲載の参考文献
1) Ohmori T : Advances in gene therapy for hemophilia : basis, current status, and future perspectives. Int J Hematol 111 : 31-41, 2020.
PubMed
2) Kay MA, Manno CS, Ragni MV, et al : Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. nature Nat Genet 24 : 257-261, 2000.
 
3) Manno CS, Pierce GF, Arruda VR, et al : Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12 : 342-347, 2006.
PubMed
4) Nathwani AC, Tuddenham EG, Rangarajan S, et al : Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365 : 2357-2365, 2011.
PubMed
5) George LA, Sullivan SK, Giermasz A, et al : Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. N Engl J Med 377 : 2215-2227, 2017.
PubMed
6) Pipe SW, Leebeek FWG, Recht M, et al : Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med 388 : 706-718, 2023.
PubMed
7) Chowdary P, Shapiro S, Makris M, et al : Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B. N Engl J Med 387 : 237-247, 2022.
PubMed
8) Xue F, Li H, Wu X, et al : Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B : a single-centre, single-arm, phase 1, pilot trial. Lancet Haematol 9 : e504-e513, 2022.
 
9) Rangarajan S, Walsh L, Lester W, et al : AAV5-Factor VIII Gene Transfer in Severe Hemophilia A. N Engl J Med 377 : 2519-2530, 2017.
PubMed
10) Ozelo MC, Mahlangu J, Pasi KJ, et al : Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med 386 : 1013-1025, 2022.
PubMed
11) George LA, Monahan PE, Eyster ME, et al : Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. N Engl J Med 385 : 1961-1973, 2021.
PubMed
12) Kashiwakura Y, Baatartsogt N, Yamazaki S, et al : The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs. Mol Ther Methods Clin Dev 27 : 404-414, 2022.
PubMed
13) Baatartsogt N, Kashiwakura Y, Hiramoto T, et al : Successful Liver Transduction by Readministration of Different Adeno-Associated Virus Vector Serotypes in Mice. J Gene Med 25 : e3505, 2023.
PubMed
14) Roth DA, Tawa NE Jr, O'Brien JM, et al : Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 344 : 1735-1742, 2001.
PubMed
P.237 掲載の参考文献
1) von Willebrand EA : Hereditar pseudohe-motifi. Svenska Lakaresallskapets Handlin-gar 67 : 87-112, 1926.
 
2) 松下正 : von Willebrand病 type1・3. 別冊日本臨牀血液症候群 (第2版) II, p557-563, 2013.
 
3) Sadler JE : A revised classification of von Willebrand disease. For the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 71 : 520-525, 1994.
PubMed
4) von Willebrand病の診療ガイドライン作成委員会 : von Willebrand病の診療ガイドライン 2021年版. 血栓止血誌 32 : 413-481, 2021.
 
5) 血液凝固異常症全国調査運営委員会 : 血液凝固異常症全国調査 令和4年度報告書, 2023.
 
6) Gill JC, Endres-Brooks J, Bauer PJ, et al : The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69 : 1691-1695, 1987.
PubMed
7) Zhang ZP, Blomback M, Nyman D, et al : Mutations of von Willebrand factor gene in families with von Willebrand disease in the Aland Islands. Proc Natl Acad Sci U S A 90 : 7937-7940, 1993.
PubMed
8) Zhang ZP, Lindstedt M, Falk G, et al : Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet 51 : 850-858, 1992.
PubMed
9) Castaman G, Linari S : Diagnosis and Treatment of von Willebrand Disease and Rare Bleeding Disorders. J Clin Med 6 : 45, 2017.
PubMed
10) Mannucci PM, Bettega D, Cattaneo M : Patterns of development of tachyphylaxis in patients with haemophilia and von Willebrand disease after repeated doses of desmopressin (DDAVP). Br J Haematol 82 : 87-93, 1992.
PubMed
11) Mannucci PM, Lusher JM : Desmopressin and thrombosis. Lancet 2 : 675-676, 1989.
PubMed
12) Mannucci PM, Kempton C, Millar C, et al : Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method : a prospective clinical trial. Blood 122 : 648-657, 2013.
 
13) Franchini M, Mannucci PM : Alloantibodies in von Willebrand Disease. Semin Thromb Hemost 44 : 590-594, 2018.
PubMed
14) Mannucci PM, Ruggeri ZM, Ciavarella N, et al : Precipitating antibodies to factor VIII/von Willebrand factor in von Willebrand's disease : effects on replacement therapy. Blood 57 : 25-31, 1981.
PubMed
15) Mannucci PM : Treatment of von Willebrand's Disease. N Engl J Med 351 : 683-694, 2004.
PubMed
P.241 掲載の参考文献
1) von Willebrand病の診療ガイドライン作成委員会 : von Willebrand病の診療ガイドライン 2021年版. 血栓止血誌 32 : 413-481, 2021.
 
2) 鈴木敦夫 : 凝固因子活性およびvon Willebrand 因子測定の現状と課題. 日本検査血液学会雑誌 23 : S88, 2022.
 
3) 松下正 : von Willebrand病 type2・血小板型. 別冊日本臨牀 血液症候群 (第2版) II, p564-568, 2013.
 
4) O'Brien LA, Sutherland JJ, Weaver DF, et al : Theoretical structural explanation for Group I and Group II, type 2A von Willebrand disease mutations. J Thromb Haemost 3 : 796-797, 2005.
 
5) Ozeki M, Kunishima S, Kasahara K, et al : A family having type 2B von Willebrand disease with an R1306W mutation : Severe thrombocytopenia leads to the normalization of high molecular weight multimers. Thromb Res 125 : e17-e22, 2010.
 
6) Federici AB, Mannucci PM, Castaman G, et al : Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B : a cohort study of 67 patients. Blood 113 : 526-534, 2009.
PubMed
7) Jackson SC, Sinclair GD, Cloutier S, et al : The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 113 : 3348-3351, 2009.
PubMed
8) Rabinowitz I, Tuley EA, Mancuso DJ, et al : von Willebrand disease type B : a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib. Proc Natl Acad Sci U S A 89 : 9846-9849, 1992.
 
9) Mazurier C, Meyer D : Factor VIII binding assay of von Willebrand factor and the diagnosis of type 2N von Willebrand disease-results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 76 : 270-274, 1996.
 
10) Marchese P, Murata M, Mazzucato M, et al : Identification of three tyrosine residues of glycoprotein Ib alpha with distinct roles in von Willebrand factor and alpha-thrombin binding. J Biol Chem 270 : 9571-9578, 1995.
 
11) Takahashi H, Murata M, Moriki T, et al : Substitution of Val for Met at residue 239 of platelet glycoprotein Ib alpha in Japanese patients with platelet-type von Willebrand disease. Blood 85 : 727-733, 1995.
PubMed
12) Federici AB, Mazurier C, Berntorp E, et al : Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease : results of a multicenter European study. Blood 103 : 2032-2038, 2004.
PubMed
P.246 掲載の参考文献
1) Moroi M, Aoki N : Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 251 : 5956-5965, 1976.
PubMed
2) Bangert K, Johnsen AH, Christensen U, et al : Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J 291 (Pt 2) : 623-625, 1993.
 
3) Collen D, Wiman B : Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood 53 : 313-324, 1979.
PubMed
4) Abdul S, Dekkers DHW, Ariens RAS, et al : On the localization of the cleavage site in human alpha-2-antiplasmin, involved in the generation of the non-plasminogen binding form. J Thromb Haemost 18 : 1162-1170, 2020.
PubMed
5) Sasaki T, Morita T, Iwanaga S : Identification of the plasminogen-binding site of human alpha 2-plasmin inhibitor. J Biochem 99 : 1699-1705, 1986.
PubMed
6) Coughlin PB : Antiplasmin : the forgotten serpin? FEBS J 272 : 4852-4857, 2005.
PubMed
7) Sumi Y, Ichikawa Y, Nakamura Y, et al : Expression and characterization of pro alpha 2-plasmin inhibitor. J Biochem 106 : 703-707, 1989.
PubMed
8) Miura O, Hirosawa S, Kato A, et al : Molecular basis for congenital deficiency of alpha 2-plasmin inhibitor. A frameshift mutation leading to elongation of the deduced amino acid sequence. J Clin Invest 83 : 1598-1604, 1989.
PubMed
9) Miura O, Sugahara Y, Aoki N : Hereditary alpha 2-plasmin inhibitor deficiency caused by a transport-deficient mutation (alpha 2-PI-Okinawa). Deletion of Glu137 by a trinucleotide deletion blocks intracellular transport. J Biol Chem 264 : 18213-18219, 1989.
PubMed
10) Holmes WE, Lijnen HR, Nelles L, et al : Alpha 2-antiplasmin Enschede : alanine insertion and abolition of plasmin inhibitory activity. Science 238 : 209-211, 1987.
PubMed
11) Aoki N, Saito H, Kamiya T, et al : Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency. J Clin Invest 63 : 877-884, 1979.
PubMed
12) Jain S, Acharya SS : Inherited disorders of the fibrinolytic pathway. Transfus Apher Sci 58 : 572-577, 2019.
PubMed
13) Lijnen HR, Okada K, Matsuo O, et al : Alpha2-antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 93 : 2274-2281, 1999.
PubMed
14) Mehic D, Pabinger I, Ay C, et al : Fibrinolysis and bleeding of unknown cause. Res Pract Thromb Haemost 5 : e12511, 2021.
PubMed
15) Aoki N, Harpel PC : Inhibitors of the fibrinolytic enzyme system. Semin Thromb Hemost 10 : 24-41, 1984.
PubMed
16) 窓岩清治 : α2-プラスミン・インヒビターとヒスチジンリッチ・グリコプロテイン. 新・血栓止血学血管学 抗凝固と線溶 2015 : 89-97. 金芳堂. [https://www.molcom.jp/products/detail/102109/]
 
17) Saes JL, Schols SEM, van Heerde WL, et al : Hemorrhagic disorders of fibrinolysis : a clinical review. J Thromb Haemost 16 : 1498-1509, 2018.
 
P.251 掲載の参考文献
1) Madoiwa S, Komatsu N, Mimuro J, et al : Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation. Blood 94 : 475-482, 1999.
PubMed
2) Eriksson P, Kallin B, van't Hooft FM, et al : Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A 92 : 1851-1855, 1995.
PubMed
3) Fay WP, Parker AC, Condrey LR, et al : Human plasminogen activator inhibitor-1 (PAI-1) deficiency : characterization of a large kindred with a null mutation in the PAI-1 gene. Blood 90 : 204-208, 1997.
 
4) Schleef RR, Higgins DL, Pillemer E, et al : Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. J Clin Invest 83 : 1747-1752, 1989.
PubMed
5) Dieval J, Nguyen G, Gross S, et al : A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1. Blood 77 : 528-532, 1991.
 
6) Fay WP, Shapiro AD, Shih JL, et al : Brief report : complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med 327 : 1729-1733, 1992.
PubMed
7) Iwaki T, Tanaka A, Miyawaki Y, et al : Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. J Thromb Haemost 9 : 1200-1206, 2011.
PubMed
8) 宮澤幸久 : 平成18年度診療報酬改定-訂正と追補-. 臨床病理 54 : 526-530, 2006.
Medical*Online
9) Urano T, Castellino FJ, Ihara H, et al : Activated protein C attenuates coagulation-associated over-expression of fibrinolytic activity by suppressing the thrombin-dependent inactivation of PAI-1. J Thromb Haemost 1 : 2615-2620, 2003.
PubMed
10) Urano T, Sumiyoshi K, Pietraszek MH, et al : PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA. Thromb Haemost 66 : 474-478, 1991.
 
11) Urano T, Sakakibara K, Rydzewski A, et al : Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Thromb Haemost 63 : 82-86, 1990.
PubMed
P.257 掲載の参考文献
1) 後天性血友病A診療ガイドライン作成委員会 : 後天性血友病A診療ガイドライン 2017年改訂版. 血栓止血会誌 28 : 715-747, 2017.
 
2) Collins PW, Hirsch S, Baglin TP, et al : Acquired hemophilia A in the United Kingdom : a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood 109 : 1870-1877, 2007.
PubMed
3) 田中一郎, 天野景裕, 瀧正志, ほか : わが国における後天性凝固因子インヒビターの実態に関する3年間の継続調査-予後因子に関する検討-. 血栓止血会誌 19 : 140-153, 2008.
 
4) Ogawa Y, Amano K, Matsuo-Tezuka Y, et al : ORIHIME study : real-world treatment patterns and clinical outcomes of 338 patients with acquired hemophilia A from a Japanese administrative database. Int J Hematol 117 : 44-55, 2023.
PubMed
5) Amisha F, Saluja P, Malik P, et al : Acquired hemophilia A (AHA) due to anti-SARS-CoV-2 vaccination : A systematic review. EJHaem 4 : 532-543, 2023.
PubMed
6) Tiede A, et al : Acquired bleeding disorders. Haemophilia 28 (Suppl 4) : 68-76, 2022.
 
7) Tiede A, Collins P, Knoebl P, et al : International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica 105 : 1791-1801, 2020.
PubMed
8) Shima M, Amano K, Ogawa Y, et al : A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost 21 : 534-545, 2023.
PubMed
9) Baudo F, Collins P, Huth-Kuhne A, et al : Management of bleeding in acquired hemophilia A : results from the European Acquired Haemophilia (EACH2) Registry. Blood 120 : 39-46, 2012.
 
10) Lindahl R, Nummi V, Lehtinen AE, et al : Acquired Haemophilia A in four north European countries : survey of 181 patients. Br J Haematol 201 : 326-333, 2023.
PubMed
11) Ehrlich HJ, Henzl MJ, Gomperts ED : Safety of factor VIII inhibitor bypass activity (FEIBA) : 10-year compilation of thrombotic adverse events. Haemophilia 8 : 83-90, 2002.
PubMed
12) Remmington T, Smith S : Rituximab for eradicating inhibitors in people with acquired haemophilia A. Cochrane Database Syst Rev 8 : CD011907, 2021.
PubMed
13) Pasca S, Zanon E, Mannucci PM, et al : Emicizumab in acquired hemophilia A : pros and cons of a new approach to the prevention and treatment of bleeding. Blood Transfus, 2023. (DOI : 10.2450/2023.0247-22)
 
P.262 掲載の参考文献
1) Knobl P, Lechner K : Acquired factor V inhibitors. Baillieres Clin Haematol 11 : 305-318, 1998.
PubMed
2) Ang AL, Kuperan P, Ng CH, et al : Acquired factor V inhibitor. A problem-based systematic review. Thromb Haemost 101 : 852-859, 2009.
PubMed
3) Franchini M, Lippi G : Acquired factor V inhibitors : a systematic review. J Thromb Thrombolysis 31 : 449-457, 2011.
PubMed
4) Boland F, Shreenivas AV : Acquired factor V inhibitors : a review of literature. Ann Hematol Oncol 4 : 1168, 2017.
 
5) Ichinose A, Osaki T, Souri M : A Review of Coagulation Abnormalities of Autoimmune Acquired Factor V Deficiency with a Focus on Japan. Semin Thromb Hemost 48 : 206-218, 2022.
PubMed
6) Matsumoto T, Nogami K, Shima M : Coagulation function and mechanisms in various clinical phenotypes of patients with acquired factor V inhibitors. J Thromb Haemost 12 : 1503-1512, 2014.
PubMed
7) Kalafatis M, Simioni P, Tormene D, et al : Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood 99 : 3985-3992, 2002.
PubMed
8) 難病情報センター : 自己免疫性後天性凝固因子欠乏症 (指定難病288). [https://www.nanbyou.or.jp/entry/4649]
 
9) Nesheim ME, Nichols WL, Cole TL, et al : Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 77 : 405-415, 1986.
PubMed
10) 一瀬白帝 : わが国における自己免疫性凝固因子欠乏症の実態と診療ガイド. 日本血栓止血学会誌 29 : 251-261, 2018.
 
P.267 掲載の参考文献
1) Muszbek L, Katona E : Diagnosis and Management of Congenital and Acquired FXIII Deficiencies. Semin Thromb Hemost 42 : 429-439, 2016.
PubMed
2) 難病情報センター : 自己免疫性後天性凝固因子欠乏症 (指定難病288). [https://www.nanbyou.or.jp/entry/4649]
 
3) Ichinose A, Souri M ; Japanese collaborative research group on "Acquired haemorrha-philia due to factor XIII deficiency" : As many as 12 cases with haemorrhagic acquired factor XIII deficiency due to its inhibitors were recently found in Japan. Thromb Haemost 105 : 925-927, 2011.
 
4) Ichinose A, Osaki T, Souri M, et al : Clinical features of 32 new Japanese cases with autoimmune haemorrha-philia due to anti-factor XIII antibodies. Haemophilia 21 : 653-658, 2015.
PubMed
5) Ichinose A, Osaki T, Souri M : Pathological coagulation parameters in as many as 54 patients with autoimmune acquired factor XIII deficiency due to anti-factor XIII autoantibodies. Haemophilia 27 : 454-462, 2021.
 
6) 自己免疫性出血病 FXIII/13 日本血栓止血学会診療ガイド作成委員会 : 自己免疫性出血病 FXIII/13 診療ガイド. 血栓止血誌 28 : 393-420, 2017.
 
7) Muszbek L, Penzes K, Katona E : Auto- and alloantibodies against factor XIII : laboratory diagnosis and clinical consequences. J Thromb Haemost 16 : 822-832, 2018.
PubMed
8) Hayashi T, Kadohira Y, Morishita E, et al : A case of acquired FXIII deficiency with severe bleeding symptoms. Haemophilia 18 : 618-620, 2012.
PubMed
9) 自己免疫性出血病 FXIII/13 日本血栓止血学会診断基準作成委員会 : 自己免疫性出血病 FXIII/13 診断ガイド. 血栓止血誌 26 : 658-668, 2015.
 
10) Osaki T, Yokoyama C, Magari Y, et al : Novel Immunochromatographic Test for Anti-factor XIII B Subunit Autoantibodies to Diagnose Autoimmune Acquired Factor XIII Deficiency. Thromb Haemost 123 : 793-803, 2023.
PubMed
11) Franchini M, Frattini F, Crestani S, et al : Acquired FXIII inhibitors : a systematic review. J Thromb Thrombolysis 36 : 109-114, 2013.
PubMed
P.277 掲載の参考文献
1) Martinod K, Deppermann C : Immunothrombosis and thromboinflammation in host defense and disease. Platelets 32 : 314-324, 2021.
PubMed
2) Cox D : Sepsis-it is all about the platelets. Front Immunol 14 : 1210219, 2023.
PubMed
3) Adelborg K, Larsen JB, Hvas AM : Disseminated intravascular coagulation : epidemiology, biomarkers, and management. Br J Haematol 192 : 803-818, 2021.
PubMed
4) Taylor FB Jr, Toh CH, Hoots WK, : Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 86 : 1327-1330, 2001.
 
5) Asakura H, Takahashi H, Uchiyama T, : Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J 14 : 42, 2016.
PubMed
6) 日本血栓止血学会 : DIC診断基準 2017年版. [https://www.jsth.org/wordpress/guideline]
 
7) Connors JM, Levy JH : COVID-19 and its implications for thrombosis and anticoagulation. Blood 135 : 2033-2040, 2020.
PubMed
8) Gando S, Iba T, Eguchi Y, : A multicenter, prospective validation of disseminated intravascular coagulation diagnostic criteria for critically ill patients : comparing current criteria. Crit Care Med 34 : 625-631, 2006.
PubMed
9) 厚生省血液凝固異常症調査研究班 : DIC診断基準-1988年改正-. [https://www.mhlw.go.jp/shingi/2009/03/dl/s0310-8k_0004.pdf]
 
10) 日本産科婦人科・新生児血液学会 : 暫定版産科DIC診断基準. 「産科DIC診断基準 (スコア) 」を2022年6月に改訂. [http://www.jsognh.jp/dic/]
 
11) 日本血栓止血学会学術標準化委員会DIC部会 : 科学的根拠に基づいた感染症に伴うDIC治療のエキスパートコンセンサス. 日本血栓止血学会誌 20 : 77-113, 2009. [https://www.jsth.org/wordpress/wp-content/uploads/2015/04/DIC.pdf]
 
12) Bernard GR, Vincent JL, Laterre PF, : Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 : 699-709, 2001.
PubMed
13) Eichacker PQ, Natanson C, Danner RL : Surviving sepsis-practice guidelines, marketing campaigns, and Eli Lilly. N Engl J Med 355 : 1640-1642, 2006.
 
14) Vincent JL, Ramesh MK, Ernest D, : A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41 : 2069-2079, 2013.
 
15) Squizzato A, Hunt BJ, Kinasewitz GT, : Supportive management strategies for disseminated intravascular coagulation. An international consensus. Thromb Haemost 115 : 896-904, 2016.
PubMed
16) Warren BL, Eid A, Singer P, : Caring for the critically ill patient. High-dose antithrombin III in severe sepsis : a randomized controlled trial. JAMA 286 : 1869-1878, 2001.
PubMed
17) Abraham E, Reinhart K, Opal S, : Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis : a randomized controlled trial. JAMA 290 : 238-247, 2003.
PubMed
P.282 掲載の参考文献
1) Kasabach KH, Merritt KK : Capillary hemangioma with extensive purpura. Am J Dis Child 59 : 1063-1070, 1940.
 
2) O'Rafferty C, O'Regan GM, Irvine AD, et al : Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon. Br J Haematol 171 : 38-51, 2015.
PubMed
3) 令和2-4年度厚生労働科学研究費難治性疾患政策研究事業「難治性血管腫・脈管奇形・血管奇形・リンパ管腫・リンパ管腫症および関連疾患についての調査研究」班 : 血管腫・脈管奇形・血管奇形・リンパ管奇形・リンパ管腫症診療ガイドライン 2022 (第3版).
 
4) Ji Y, Yang K, Peng S, et al : Kaposiform haemangioendothelioma : clinical features, complications and risk factors for Kasabach-Merritt phenomenon. Br J Dermatol 179 : 457-463, 2018.
 
5) Croteau SE, Liang MG, Kozakewich HP, et al : Kaposiform hemangioendothelioma : atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr 162 : 142-147, 2013.
PubMed
6) Mahajan P, Margolin J, Iacobas I : Kasabach-Merritt Phenomenon : Classic presentation and management options. Clin Med Insights Blood Disord 10 : 1179545X17699849, 2017.
PubMed
7) Lei HZ, Sun B, Ma YC, et al : Retrospective study on the outcomes of infantile tufted angioma complicated by Kasabach-Merritt phenomenon. Clin Chim Acta 486 : 199-204, 2018.
PubMed
8) Shen W, Cui J, Chen J, et al : Treating kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon by intralesional injection of absolute ethanol. J Craniofac Surg 25 : 2188-2191, 2014.
PubMed
9) 堀口明由美, 荒川ゆうき, 柳将人, ほか : 新生児期に放射線治療を行ったKasabach-Merritt現象における成長障害. 日小児会誌 125 : 1041-1047, 2021.
 
10) Wu HW, Wang X, Zhang L, et al : Interferon-alpha therapy for refracory kaposiform hemangiendothelioma : a single-center experience. Sci Reo 6 : 36261, 2016.
 
11) Chiu YE, Drolet BA, Blei F, et al : Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon. Pediatr Blood Cancer 59 : 934-938, 2012.
PubMed
12) 大和田淳也, 安藤友久, 中舘尚也, ほか : vincristineが奏効したKasabach-Merritt現象の3例. 小児科診療 80 : 641-644, 2017.
Medical*Online
13) Freixo C, Ferreira V, Martins J, et al : Efficacy and safety of sirolimus in the treatment of vascular anomalies : A systematic review. J Vasc Surg 71 : 318-327, 2020.
 
14) Ji Y, Chen S, Xiang B, et al : Sirolimus for the treatment of progressive kaposiform hemangioendothelioma : A multicenter retrospective study. Int J Cancer 141 : 848-855, 2017.
 
15) 竹森千晃, 川口晃司, 高橋郁子, ほか : シロリムスが奏功した脊柱管浸潤を合併した治療抵抗性Kaposi型血管内皮腫. 日小児会誌 122 : 1333-1340, 2018.
 
P.286 掲載の参考文献
1) 白幡聡, 伊藤進, 高橋幸博, ほか : 新生児・乳児ビタミンK欠乏性出血症に対するビタミンK製剤投与の改訂ガイドライン (修正版). 日児誌 115 : 705-712, 2011
 
2) 乾あやの : 特発性乳児ビタミンK欠乏症. 別冊日本臨牀血液症候群 (第2版) II, p609-612, 日本臨牀社, 2013.
 
3) 塚本桂子 : ビタミンK欠乏性出血症. 小児内科 54 : 884-890, 2022.
Medical*Online
4) Takahashi D, Shirahata A, Itoh S, et al : Vitamin K prophylaxis and late vitamin K deficiency bleeding in infants : fifth nationwide survey in Japan. Pediatr Int 53 : 897-901, 2011.
PubMed
5) 日本小児科学会, ほか : 新生児と乳児のビタミンK欠乏性出血症発症予防に関する提言. [https://www.jpeds.or.jp/uploads/files/20211130_VK_teigen.pdf]
 
P.289 掲載の参考文献
1) 塚本桂子 : ビタミンK欠乏性出血症. 小児内科 54 (増刊) : 884-890, 2022.
Medical*Online
2) 熊本大学病院輸血・細胞治療部 : ビタミンKサイクル. [http://square.umin.ac.jp/transfusion-kuh/related/VitKcycle/index.html]
 
3) Greer FR : Vitamin K in human milk-still not enough Acta Paediatr 93 : 449-450, 2020.
 
4) Kojima T, Asoh M, Yamawaki N, et al : Vitamin K concentrations in the maternal milk of Japanese women. Acta Paediatr 93 : 457-463, 2004.
PubMed
5) Araki S, Shirahata A, et al : Vitamin K deficiency bleeding in infancy. Nutrients 12 : 780, 2020.
PubMed
6) 白幡聡, 伊藤進, 高橋幸博, ほか : 新生児・乳児ビタミンK欠乏性出血症に対するビタミンK製剤投与の改訂ガイドライン (修正版). 日児誌 115 : 705-712, 2011.
 
7) 乾あやの : ビタミンK欠乏性出血. 別冊日本臨牀血液症候群 (第2版) II, p612-616, 日本臨牀社, 2013.
 
8) Golding J, Green wood R, Birmingham K, et al : Childhood cancer, intramuscular vitamin K, and pethidine given during labour. BMJ 305 : 341-346, 1992.
 
P.292 掲載の参考文献
1) Cunningham MT, Brandt JT, Laposata M, et al : Laboratory diagnosis of dysfibrinogenemia. Arch Pathol Lab Med 126 : 499-505, 2002.
PubMed
2) Lane DA, Scully MF, Thomas DP, et al : Acquired dysfibrinogenaemia in acute and chronic liver disease. Br J Haematol 35 : 301-308, 1977.
PubMed
3) Reganon E, Vila V, Aznar J, et al : Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia. Thromb Res 46 : 705-714, 1987.
PubMed
4) Levy J, Pettei MJ, Weitz JI : Dysfibrinogenemia in obstructive liver disease. J Pediatr Gastroenterol Nutr 6 : 967-970, 1987.
PubMed
5) Francis JL, Armstrong DJ : Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 35 : 667-672, 1982.
PubMed
6) Wilde JT, Thomas WE, Lane DA, et al : Acquired dysfibrinogenaemia masquerading as disseminated intravascular coagulation in acute pancreatitis. J Clin Pathol 41 : 615-618, 1988.
PubMed
7) Gralnick HR, Givelber H, Abrams E : Dysfibrinogenemia associated with hepatoma. Increased carbohydrate content of the fibrinogen molecule. N Engl J Med 299 : 221-226, 1978.
PubMed
8) Kotlin R, Sobotkova A, Riedel T, et al : Acquired dysfibrinogenemia secondary to multiple myeloma. Acta Haematol 120 : 75-81, 2008.
PubMed
9) Ashby MA, Lazarchick J : Acquired dysfibrinogenemia secondary to mithramycin toxicity. Am J Med Sci 292 : 53-55, 1986.
PubMed
10) Arai S, Kamijo T, Takezawa Y, et al : Acquired dysfibrinogenemia : monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation. Int J Hematol 112 : 96-104, 2020.
 
11) Siddiq N, Bergstrom C, Anderson LD Jr, et al : Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma. BMJ Case Rep 12 : e229312, 2019.
PubMed
12) Mori T, Murata M, Wakui M, et al : Acquired dysfibrinogenemia following allogeneic bone marrow transplantation. Am J Hematol 56 : 294-295, 1997.
PubMed
13) Martinez J, MacDonald KA, Palascak JE : The role of sialic acid in the dysfibrinogenemia associated with liver disease : distribution of sialic acid on the constituent chains. Blood 61 : 1196-1202, 1983.
PubMed
14) Herbert JM, Bernat A, Chatenet-Duchene L : Effect of ciprofibrate on fibrinogen synthesis in vitro on hepatoma cells and in vivo in genetically obese Zucker rats. Blood Coagul Fibrinolysis 10 : 239-244, 1999.
PubMed
P.298 掲載の参考文献
1) 日笠聡, 渥美達也, 石黒精, ほか : von Willebrand病の診療ガイドライン 2021年版. 日本血栓止血学会誌 32 : 413-481, 2021.
 
2) Federici AB, Budde U, Castaman G, et al : Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome : a 2013 update. Semin Thromb Hemost 39 : 191-201, 2013.
 
3) Budde U, Bergmann F, Michiels JJ : Acquired von Willebrand syndrome : experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 28 : 227-238, 2002.
 
4) Tiede A, Priesack J, Werwitzke S, et al : Diagnostic workup of patients with acquired von Willebrand syndrome : a retrospective single-centre cohort study. J Thromb Haemost 6 : 569-576, 2008.
 
5) Tiede A : Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res 130 (Suppl 2) : S2-S6, 2012.
 

書評

最近チェックした商品履歴

Loading...